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ABSTRACT 
 
 
Hypericum perforatum as an Antimycobacterial Agent and Its Implications  
as an Additional Tuberculosis Medication 
 
by 
 
 
Trent W. Mortensen, Master of Science 
 
Utah State University, 2010 
 
 
Major Professor: Dr. Charles D. Miller 
Department: Biological Engineering  
 
 
An immediate demand exists for new tuberculosis (TB) antibiotics due to the 
ever-increasing spread of drug-resistant strains.  The drug-development process goes 
through four phases, the first (Phase 0) of which is to demonstrate and investigate drug 
effectiveness and toxicity.  This research investigated the effectiveness of the Hypericum 
perforatum herb (commonly St. John’s wort (SJW)) in its growth inhibition of 
mycobacteria and its viability effect on human lung cells. 
Organic-solvent SJW extracts were effective at inhibiting every nonpathogenic 
genetically sequenced Mycobacterium isolate currently available (six isolates) in 
preliminary studies.  Quantitative studies of five Mycobacterium isolates showed an order 
of concentration sensitivity to the SJW methanol (MeOH) extract as (high to low) M. 
JLS, M. KMS, M. phlei (not sequenced), M. MCS, B. subtilis, M. smegmatis, and E. coli, 
with minimal bactericidal concentrations (MBCs) ranging from 0.33-2.66 mg extract/ml.  
The SJW compounds hyperforin (Hfn), hypericin (Hpn), and pseudohypericin (Phn) were 
iv 
	  
quantified using a novel HPLC method that utilized common HPLC equipment. A crude 
MeOH extract solution of 133 mg extract/ml contained 2.26 mg Hfn/ml, 0.77 mg 
Hpn/ml, and 2.67 mg Phn/ml.  Purified Hfn had a MBC of between 6-13 µg/ml for M. 
JLS in the absence of Tween 80.  Tween 80 repressed Hfn (46 µg/ml) inhibition of M. 
JLS at ≥ 0.025% (v/v).  Purified Hpn and Phn showed no inhibition of M. JLS at all 
assayed concentrations, which were ≤ 27 µg/ml and ≤ 25 µg/ml, respectively.  Inhibitory 
results from the five quantitatively assayed Mycobacterium samples could be 
extrapolated to M. tuberculosis, as these isolates have as high as 72% genetic homology 
to the pathogen.  
The crude MeOH extract and Hfn were lethal to the human carcinomic alveolar 
epithelial lung cell line A549 at 1.3 mg extract/ml (crude extract) and ≥ 11 µg/ml (Hfn), 
with a Hfn LD50 of 3-6 µg/ml (5.6-11.2 µmol/L).  Because Hfn is antiproliferative to a 
list of other carcinomic cell lines in the same concentration range, the A549 cell line may 
be added to that list.  The addition of M. JLS cells (5x106 cells/cm2) to penicillin-
streptomycin-containing A549 culture (which killed the bacteria) did not affect A549 
viability. 
 
 
 
 (140 pages) 
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CHAPTER 1 
 
INTRODUCTION 
 
 
The Need for Additional Mycobacterial Antibiotics 
 
 
The Global Tuberculosis Problem 
 
Among diseases caused by the genus Mycobacterium, tuberculosis (TB) is the 
most common.  This infectious disease is caused by Mycobacterium tuberculosis and 
affects about one-third of the world’s population.  About 10% of those infected develop 
the active form of the disease in their lifetime, which usually results in pulmonary (lung) 
infection but can also infect other areas of the body (Smith, 2003).  Those who do not 
develop the active disease maintain the latent disease (Jasmer et al., 2002).  In 2008, 
there were 9.4 million new TB cases and 1.8 million TB-related deaths (WHO, 2009).     
TB treatment has gone through several stages, from the fresh-air sanatoriums of 
the 19th century to the chemotherapeutic treatments of today (Snider, 1997).  Current 
treatment regimens rely on strategies utilizing first- and second-line drugs, with the first-
line drugs being more effective and having fewer side effects (Blumberg et al., 2003).  
Lack of adherence to drug regimens has led to the evolution of drug-resistant TB strains 
that do not respond to the best first-line medications and, in some cases, the best second-
line medications (Sharma and Mohan, 2006; CDC, 2010).  Therefore, novel TB 
medications are needed that shorten regimen duration and improve the treatment of drug-
resistant and latent TB (O’Brien and Nunn, 2001).  The purpose of this research was to 
investigate the feasibility of using the Hypericum perforatum herb (or more commonly 
St. John’s wort) for producing such medications.  	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Hypothesis 
The Hypericum perforatum herb contains quantifiable compounds that cause cell 
death of Mycobacterium isolates but not of human lung cells.   
 
Objectives 
 
1. Establish an efficient, accurate, and precise high-performance liquid 
chromatography (HPLC) method for quantification of the SJW compounds 
pseudohypericin, hyperforin, and hypericin.   
2. Demonstrate inhibitory effectiveness of SJW compounds on mycobacteria and 
determine the effective concentrations. 
3. Determine the effect of SJW compounds on the viability of human alveolar 
epithelial cells.   
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CHAPTER 2 
 
REVIEW OF LITERATURE 
	  
 
Mycobacteria 
 
 
Genus Properties 
 
M. tuberculosis and others of the genus Mycobacterium have distinct properties 
that set them apart from other bacteria.  With regard to scientific classification, 
mycobacteria are their own family, Mycobacteriaceae, under the suborder 
Corynebacterineae, under the order Actinomycetales, under the phylum Actinobacteria in 
the Bacteria kingdom (NCBI, 2010).   
Mycobacteria are aerobic and generally nonmotile.  Since this genus does not 
retain a crystal-violet stain, it is classified as an acid-fast Gram-positive bacteria because 
it does not have an outer membrane.  Mycobacteria have characteristically thick, waxy, 
cell walls largely composed of mycolic acids.  This cell wall is composed of the 
following layers (from outer to inner): outer layer (capsule) lipid, mycolic acid, 
arabinogalactan polysaccharide, peptidoglycan, periplasm, and plasma membrane (Daffe 
and Reyrat, 2008).  Mycobacteria are bacilli that can range in size from 0.2-0.7 µm wide 
and 1.0-10 µm long (Holt et al., 1994).  They can be classified in their pigmentation as 
follows: photochromagens, which produce non-pigmented colonies in the dark and 
pigmented colonies in the light, scotochromogens, which always produce deep yellow or 
orange colonies, and non-chromogens, which have a pale yellow or tan color (M. 
tuberculosis is of this type) (Jenkins, 1981).  Mycobacteria can be found in water, soil, or 
animal tissues or secretions.   
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Mycobacteria are relatively slow growing, with those that form visible colonies 
within seven days being called rapid growers, and those taking longer being called slow 
growers (Wayne and Kubica, 1986). They are relatively flexible in their growth 
conditions, with growth temperatures (depending on strain) ranging from 25˚C to over 
50˚C and the ability to grow on several types of media with simple nitrogen, carbon, and 
energy sources (Allen, 1998).  Tween 80, a surfactant, is often added to mycobacterial 
liquid cultures to lessen clumping, which is often an issue.  However, Tween 80 can also 
alter the outmost layer of the cell wall (Parish and Stoker, 1998).        
Mycobacteria are known to have functional secretion pathways, including Sec, 
Tat, and mycobacterial-specific pathways, with orthologs of all known necessary 
secretion proteins for these pathways present in mycobacterial genomes.  Secreted 
proteins in pathogenic mycobacteria play an important part in their virulence (McCann et 
al., 2009).   
According to the National Center for Biotechnology Information (NCBI, 2010), 
there are 40 completely sequenced genome variations of 14 mycobacterium species, M. 
tuberculosis having 22 variations.  There are only six nonpathogenic Mycobacterium 
isolates in that database, all of which are considered rapid growers: M. smegmatis, M. 
gilvum PYR-GCK, M. vanbaalenii PYR-1, M. JLS, M. KMS, and M. MCS.  The latter 
five isolates are known for their ability to mineralize polyaromatic hydrocarbons (PAHs), 
with the latter three of these having been isolated by researchers at Utah State University 
(Miller et al., 2004, 2007).   
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Tuberculosis 
 
Prevalence 
 
As of 2009, information provided by the World Health Organization (WHO) 
states that TB infects one-third of the world’s population, and that 10% of those infected 
will develop the active form of TB sometime during their lifetime.  Those with active TB 
each infect 10-15 people, on average.  TB has the highest incidence in areas of poverty 
and is a leading cause of death for Human Immunodeficiency Virus (HIV)-positive 
people, making HIV-infected persons 20 to 40 times more susceptible to active TB 
development  (WHO, 2009). 
 
Pathogenesis 
  
While much about the mechanism of action for the virulence of M. tuberculosis, 
the pathogen that causes TB, remains to be learned, reviews on the subject by van Crevel 
et al. (2002) and Smith (2003) are informative.  The severity of virulence can range from 
the potent, disseminating miliary tuberculosis to the self-limiting tuberculosis pleuritis 
(Smith, 2003).  Infecting M. tuberculosis bacilli can take localization in many parts of the 
body, but usually takes residence in the lungs.  In a 1978 study (prior to the AIDS 
epidemic), it was shown that 85% of newly acquired TB cases resulted in pulmonary 
infection (Hopewell, 1994).  This is similar to a 1993 survey of 313 TB patients, which 
showed 81% of the cases as pulmonary (Miller et al., 2000).   
The events leading up to the final infection state have been studied.  The 
chronology of TB pathogenesis has been organized into four stages (Dannenberg and 
Rook, 1994; Smith, 2003).  (1) The first stage, lasting 3 to 8 weeks, begins with the 
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inhalation of aerosols containing M. tuberculosis.  The bacilli are transferred to lung 
lymph nodes once they reach the alveoli.  This creates the primary, or Ghon, complex.  
Whether or not it is possible for host macrophages to ingest and destroy the bacteria at 
this point depends on the bactericidal ability of the macrophages and on the TB virulence.  
(2) If the mycobacteria survive this step, then monocytes in the blood and other 
inflammatory cells come to the infection sites in the lung.  This second stage, or 
spreading stage, lasts about three months and consists of hematogenous spread the 
mycobacteria to other parts of the lungs or other organs.  This stage also consists of 
monocyte differentiation into macrophages and subsequent ingestion (but unsuccessful 
destruction) of the mycobacteria.   This creates a cycle of increasing numbers of both 
macrophages and mycobacteria.   
Two to three weeks after infection, T-cell lymphocytes arrive at the infection 
sites, called tubercles, and activate the macrophages to destroy the mycobacteria they 
have ingested.  This leads to the third stage (3), or inflammation stage, which begins with 
the stop of logarithmic mycobacterial growth and can last for 3 to 7 months.  Granulomas 
are formed at the infection sites, with caseous centers consisting of dead macrophages 
that are filled with mycobacteria and an encasing of fibroblasts, lymphocytes, and blood-
derived monocytes (Smith, 2003).  The last stage (4), or slowing stage, can last for up to 
three years.  In this stage, the infection may become dormant or it may spread later in life, 
depending on immune system strength.  If the immune system weakens, mycobacteria in 
the granulomas may rupture their containment, leaking into the outside environment.  
This can lead to infection elsewhere in the lungs or body.  If this happens, the outcome of 
this final stage event depends on the balance between (i) the outgrowth and killing of M. 
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tuberculosis and (ii) the extent of tissue necrosis, fibrosis, and regeneration (van Crevel et 
al., 2002). 
 
Symptoms and Methods of Diagnosis 
 
Symptoms.  Miller et al. (2000) described the most common TB symptoms in a 
1993 survey of 313 TB patients in Los Angeles County, CA, USA.  With 81% of the 
cases pulmonary, common symptoms, in order of prevalence, were as follows: cough, 
fever, fatigue, weight loss, sweats, anorexia, chest pain, diarrhea, and hemoptysis 
(coughing up blood).  Several of the symptoms were present for more than 2 weeks.   
Mantoux Tuberculin Skin Test.  According to the Mayo Clinic (2009) and Jasmer 
et al. (2002), testing for TB is done first using one or both of two tests, which are also the 
only current means of diagnosing latent TB. The first test is the Mantoux tuberculin skin 
test, which tests for a visual immune response to the purified protein derivative (PPD) of 
M. tuberculosis when this derivative is injected intracutaneously.  The level of immune 
response is determined by measuring the induration (hardened skin) diameter at the 
injection site, not the erythema (redness).    
Whole Blood Interferon-γ Assay.  The second test is the whole blood interferon-γ 
assay.  This assay tests for the presence of interferon-γ from T-lymphocytes, which have 
been produced in response to exposure to M. tuberculosis PPD.  Another version of this 
test uses a different M. tuberculosis antigen, ESAT-6, to test for release of interferon-γ if 
the first form of the blood test has complications, such as can be caused by BCG 
(Bacillus Calmette Guerin TB vaccine) (Jasmer et al., 2002).   
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Active TB Suspected.  The Mayo Clinic (2009) states that if active TB is 
suspected, follow-up tests could include chest X-ray, computerized tomography (CT) 
scan, culture tests, or nuclear acid amplification (NAA) tests.  The latter test utilizes 
polymerase chain reaction (PCR) to amplify and detect genes unique to drug-resistant 
strains.    
 
Treatment  
 
Brief History.  Scheindlin (2006) gave an overview of the history of TB treatment.  
TB treatment first saw some success with the use of fresh-air sanatoriums in the early-to-
mid 1900s, which were places of retreat (usually in the mountains) where a healthy 
atmosphere aided in recovery for victims by allowing the immune system to quarantine 
M. tuberculosis bacilli into granulomas without additional infection.  The discovery and 
isolation of M. tuberculosis by Robert Koch led to the development of the first TB 
antibiotic, streptomycin, by Waksman in 1943.  Several other antibiotics were produced 
over the next 23 years, including isoniazid, pyrazinamide, ethambutol, and rifampicin.   
First- and Second-Line TB Antibiotics.  Shah et al. (2007) stated that first-line 
antibiotics for TB today are mainly isoniazid (INH), rifampicin (RIF), ethambutol 
(EMB), and streptomycin (SM), with the Merck Manual (2009) adding rifabutin, 
rifapentine, and pyrazinamide (PZA) to this list.  Second-line drugs have been organized 
into six classes: (1) aminoglycosides other than SM (e.g., kanamycin and amikacin), (2) 
cyclic polypeptides (e.g., capreomycin), (3) fluoroquinolones (e.g., ofloxacin, 
ciprofloxacin, levofloxacin, and moxifloxacin), (4) thioamides (e.g., prothionamide and 
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ethionamide), (5) serine analogs (e.g., cycloserine and terizidone), and (6) salicylic acid 
derivatives (e.g., para-aminosalacylic acid)” (Shah et al., 2007). 
Mechanisms of Action of First-Line Antibiotics.  TB antibiotics cause 
mycobacterial inhibition through one or more of several mechanisms of action.  INH 
receives peroxidative activation by the mycobacterial enzyme KatG, which forms species 
with NAD+ and NADP+ that inhibit enzymes that synthesize lipids and nucleic acids.  It 
also forms nitric oxide species that inhibit metabolic enzymes (Timmins and Deretic, 
2006).  One of the end results of INH activity is the inhibition of mycolic acid synthesis 
(Mayer, 2010).  RIF binds bacterial RNA polymerase, preventing RNA transcription 
(Wherli, 1983).  EMB interferes with arabinan biosynthesis in the cell wall (Dover et al., 
2008).  SM interferes with aminoacyl-tRNA decoding, interfering with protein synthesis 
(Rattan et al., 1998).  It is proposed that PZA inhibits fatty acid synthase (Dover et al., 
2008).   
Treatment Regimens.  The American Thoracic Society (ATS), Centers for Disease 
Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) have 
produced an extensive document outlining recommended treatment regimens for TB 
cases of various types and giving detailed information on medications, medication 
combinations, and special treatment considerations for various patient subgroups 
(Blumberg et al., 2003).  While this information is too lengthy to be reviewed in detail 
here, it may be generally stated that treatment for drug-susceptible TB typically begins 
with two or more of the first-line drugs, including INH and RIF.  Initial treatment 
regimens depend on suspicion of severity and the presence of additional medical 
conditions, such as HIV.  Treatment then progresses to one of various other treatment 
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regimens depending on test results.  If drug-resistant TB is confirmed, treatment regimens 
employ at least three drugs to which the TB strain is susceptible in vitro.     
 
Drug-Resistant TB Strains  
  
Resistance Development.  Drug-resistant strains of TB have emerged over time 
due to the lack of adherence to drug regimens (Pablos-Mendez and Lessnau, 2000).  
When all of the TB bacilli are not destroyed, they can multiply and in rare cases develop 
a genetic mutation either through DNA replication or through gene transfer from another 
organism, which counters the mechanism of action of an antibiotic.  Such has been the 
case with several TB antibiotics, including INH and RIF of the first-line drugs and 
fluoroquinolones and the injectable drugs of the second-line medications (Rattan et al., 
1998).  Mutations have occurred in at least four enzyme-coding regions of M. 
tuberculosis, resulting in previously-targeted enzymes with altered binding sites to which 
isoniazid can no longer bind to prevent synthesis of mycolic acid.  Mutations have also 
occurred in the DNA region coding for the RNA polymerase β subunit, which is the 
binding target for rifampicin.  Once mutated a certain way, rifampicin can no longer bind 
to this subunit, and transcription goes on as usual in the cell (Sharma and Mohan, 2004).   
MDR-TB and XDR-TB.  In the early 1990’s, multi-drug resistant TB (MDR-TB) 
was discovered (Shah et al., 2007) and is defined as resistance to at least the first-line 
drugs RIF and INH (Sharma and Mohan, 2004).  In 2006, a report was jointly produced 
by the CDC and WHO describing the emergence of extensively drug-resistant TB (XDR-
TB) (CDC, 2006).  XDR-TB is defined as resistance to at least RIF and INH among first-
line drugs, resistance to any fluoroquinolone, and resistance to at least one second-line 
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injectable drug (amikacin, capreomycin, or kanamycin).  By November 2009, 57 
countries reported at least one case of XDR-TB (WHO, 2009).  Preliminary anecdotal 
evidence has also suggested some TB cases in Europe classified as extremely drug-
resistant, or XXDR (Migliori et al., 2007).   
 
The Call for Novel TB Medications 
 
In the 2002 American Thoracic Society (ATS) report, there is a call for novel 
drugs to treat TB, both drug-susceptible and drug-resistant (Blumberg et al., 2003).  
There are three reasons stated for this call: (1) the current lengthy treatment regimens, 
which last for at least 6 months and which lead to non-adherence (which contributes to 
unsuccessful treatment and drug resistance), (2) the increasing rate of drug-resistant TB 
(Espinal et al., 2001), and (3) the need for more effective treatment of latent TB infection 
(LTBI).  This need is not only due to the difficulty in producing new medications, but in 
large part to the lack of urgency felt by pharmaceutical companies (O’Brien and Vernon, 
1998; O’Brien and Nunn, 2001).     
 
Drug Development and Toxicity Testing  
 
 
Minimal Inhibitory Concentrations and  
Minimal Bactericidal Concentrations 
 
An important first step in developing a novel antibiotic is to know effective 
dosage concentrations.  Due to the variety of methods researchers have used in 
determining minimal inhibitory concentrations (MICs) and minimal bactericidal 
concentrations (MBCs), Andrews (2001) set forth methods to enable clear comparison of 
various antibiotics.  She defined MIC as the lowest concentration that will inhibit growth 
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after overnight incubation and MBC as the lowest concentration that will inhibit growth 
after subculture onto antibiotic-free media.  This definition cannot be strictly applied to 
mycobacteria, however, due to their relatively slow growth rates. (Wayne and Kubica, 
1994; Miller et al., 2004). 
 
Phases of Drug Development 
According to the United States Food and Drug Administration (FDA, 2010), 
Pacific Biolabs (PBL, 2009), and Chien et al. (2005), the process of new drug 
development goes through three clinical phases (after the preclinical phase) before it can 
be marketed.  DiMasi et al. (2003) gave mean durations of and times between the clinical 
phases.  Phase 0 is the preclinical phase.  This phase includes identification of a potential 
pharmaceutical compound, demonstration of its (or other compounds of the same 
pharmacophore) effectiveness in cell or tissue cultures, gathering of toxicity data to 
determine dosage ranges, compound characterization, animal testing, and identification of 
a lead compound for clinical testing.  Phase I (mean of 21.6 months), the first clinical 
phase, is a small-scale study on a group of healthy people to evaluate dosage and 
pharmacokinetic parameters and observe any toxicity indicators.  Phase II (mean of 25.7 
months) is a larger scale study (100-250 patients) used to demonstrate effectiveness in the 
intended population, gain information on side effects, and establish dosages for Phase III.  
Phase III (mean of 30.5 months) is a large-scale study used to gather additional data on 
efficacy and safety of the new drug.  Once this phase has been completed, a Biologics 
License Application (BLA) or New Drug Application (NDA) is submitted to the FDA.  If 
approved, the new pharmaceutical can proceed to the marketing phase.   
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Hypericum perforatum (St. John’s Wort) 
 
 
Background 
 
Hypericum perforatum, or St. John’s wort (SJW), is a perennial herb of the family 
Hypericaceae that is found in many temperate regions throughout the world.  This herb is 
considered an invasive species in many areas and grows to a height 0.3-1 m on average.  
Its leaves, 1.5-4 cm long, have pellucid glands (hence the “perforatum,” Latin for 
“perforated”).  Each plant produces seed pods and as many as 100 yellow flowers during 
the spring, with each flower consisting of five pedals that are usually 8-12 mm long 
(Kirakosyan, 2006).  The highest concentrations of bioactive components are found in the 
aerial parts of the plant, especially the generative parts, and vary in their concentration 
throughout the year (Southwell and Bourke, 2001; Butterweck, 2009).  
 
St. John’s Wort – Active Compounds 
 
Several bioactive compounds in SJW have been identified and investigated 
(Greeson et al., 2001).  Hypericin (Hpn) and pseudohypericin (Phn), which are 
napthodianthrones, and hyperforin (Hfn), a phloroglucinol, have been subjects of a 
substantial portion of SJW research focus because of their implications in human health.  
Their concentrations in SJW can vary greatly depending on variables such as harvesting 
time, temperature, and germplasm (Couceiro et al., 2006).  Chemical structures for these 
compounds are shown in Figure 2.1 (Bauer et al., 2001).   
The Phloroglucinol Hyperforin.  Hfn has been the subject of much research for its 
antidepressant (Gaster and Holroyd, 2000; Southwell and Bourke, 2001; Muller, 2003; 
Lawvere and Mahoney, 2005; Medina et al., 2006), anticancer (Agostinis et al., 2002; 
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Schempp et al., 2002; Hostanska et al., 2003; Quiney et al., 2007), anti-inflammatory 
(Tedeschi et al., 2003; Medina et al., 2006), and antibiotic activity (Gurevich et al., 1971; 
Laakmann et al., 1998; Ebrey, 1999; Schempp et al., 1999; Reichling et al., 2001; Avato 
et al., 2004; Zanoli, 2004; Beerhues, 2006; Medina et al., 2006; Milosevic and Solujic, 
2006).  In humans, Hfn has been found to reach blood concentrations of approximately 
400 ng/ml 3-3.5 hr after a 1200 mg administration of a 5% Hfn SJW extract (Biber et al., 
1998).  The maximum absorbance wavelength for this compound varies depending on pH 
and solvent used, but 270 nm is typically used for analysis (Ganzera et al., 2002; 
Fourneron and Nait-Si, 2006).  Hfn is soluble in organic solvents but completely 
insoluble in water (Holzl and Petersen, 2003). 
The Napthodianthrones Hypericin and Pseudohypericin.  Hpn and Phn (often 
grouped together as “hypericins”) are photoactive compounds (Pace, 1942; Greeson et 
al., 2001; Southwell and Bourke, 2001; Muller, 2003) and in some instances have been 
reported as antibiotic compounds (Avato et al., 2004; Milosevic and Solujic, 2006).  
However, the antimicrobial effect of Hpn “seems to be directly related to the 
simultaneous effects of radiation from the sun” (Reichling et al., 2001).  Hpn has also 
been claimed to work synergistically with Hfn in causing apoptosis in human malignant 
cells (Hostanska et al., 2003).  Phn and Hpn are also the antiviral/antiretroviral 
components of SJW (Meruelo et al., 1988; Lavie et al., 1989; Jacobson et al., 2001).   
In SJW extracts, Phn is typically found in concentrations two to four times higher 
than Hpn but can be up to ten times higher (Butterweck, 2009).  These compounds are 
fluorescent with excitation and emission spectra dependent on solvent type used (Wynn 
and Cotton, 1995) and pH (Yamazaki et al., 1993) but are usually assayed at or around 
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(excitation/emission) 315/590 nm (Bauer et al., 2001; de los Reyes and Koda, 2001).  
Absorption spectra is also pH and solvent dependent but is typically assayed at or around 
590 nm (Yamazaki et al., 1993, Nait-Si and Fourneron, 2004).  The solubility of Hpn at 
30ºC is 500 µg/ml in methanol (MeOH) and 40 µg/ml (considered insoluble) in water.  
Aqueous solubility of Hpn can be increased to 30% that of MeOH by adding 2-
hydroxypropyl-β-cyclodextrin (Holzl and Petersen, 2003).  The hypericins are also 
soluble in an ethanol (EtOH) aqueous solution up to a dilution of 25:75 EtOH:H2O, 
beyond which point colloids form (Gaind and Ganjoo, 1959).  Hpn and Phn are insoluble 
in water at ambient temperature but can be more than 40% extracted in an aqueous tea at 
temperatures of 60-80ºC (Butterweck, 2009).  Phn is slightly more soluble in polar 
solvents due to the extra hydroxyl unit in its chemical structure (Kirakosyan, 2006; 
Karioti and Bilia, 2010).  
Hypericin Photodynamic Therapy.  Hpn is one of the most potent naturally 
occurring photodynamic agents and is being researched for use as a photodynamic 
therapy (PDT) agent.  Hpn can cause both apoptosis and necrosis, depending on 
concentration and dose of light (Agostinis et al., 2002), with apoptosis occurring at lower 
Hpn concentrations than necrosis (Karioti and Bilia, 2010).  This compound is excited 
and becomes cytotoxic by wavelengths between 590-600 nm.  It inhibits protein kinase 
C, irreversibly damages the sarco/endoplasmic reticulum and other cellular membranes, 
decreases cellular pH, and inhibits mitochondrial function (Sigma-Aldrich, 2009).  Hpn is 
of great interest to the field of oncology because of the potential for direct, non-systemic 
cancer treatment.  The mode of operation has been described for Hpn PDT, which 
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ultimately leads to reactive oxygen species (ROS) and subsequent oxidative tissue 
damage (Agostinis et al., 2002; Kiesslich et al., 2006; Karioti and Bilia, 2010).  Though 
Phn is similar in chemical structure to Hpn, studies suggest that Phn is not the 
photosensitizer (Vandenbogaerde et al., 1998). 
Compound Preservation and Photoconversion.  Hfn is known to be unstable and 
degrade in the presence of light or oxygen (Gray et al., 2000; Orth and Shmidt, 2000).  A 
study by de los Reyes and Koda (2001) investigated different solvent types for 
minimizing Hfn degradation.  It was found that using acidified MeOH (pH 2.5 with 
orthophosphoric acid) for the extraction solvent preserved Hfn better than pure MeOH, 
especially at colder temperatures.  Other authors performed studies in the dark to preserve 
Hfn from light degradation (Avato et al., 2004).  While Hfn requires protection from 
light, Hpn and Phn require some exposure to light to allow the conversion of their 
protoforms.  It was found that storing a crude extract in an amber glass vial and exposing 
to wavelengths in the range of 450-750 nm prevented Hfn degradation while allowing 
conversion of the protoforms of Hpn and Phn; the optimal photoconversion range for 
these compounds is 510-540 nm (Poutaraud et al., 2001b; Ruckert et al., 2007).    
 
HPLC Quantification of SJW Compounds 
 
The Need for Quantification   
SJW is sold under various brand names and is sometimes weakly standardized, 
usually according to Hpn content (de los Reyes and Koda, 2002).  However, due to an 
increase in research on the health benefits of other SJW bioactive compounds, there is a 
push for greater regulation of these compounds as well.  Several quantification 
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techniques for SJW compounds exist, including two-dimensional proton nuclear 
magnetic resonance (NMR) (which does not require compound separation for analysis) 
(Bilia et al., 2001). However, high-performance liquid chromatography (HPLC) has been 
the method of choice for quantification of these compounds (Vollmer and Rosenson, 
2004), and efforts are still being made to develop improved HPLC methods.   
 
Existing SJW HPLC Methods   
Several HPLC methods have been developed for quantification of Hpn, Phn, and 
Hfn.  Many of these methods document thorough analysis of their accuracy and 
reproducibility and would be effective in facilities with high-end HPLC separation and 
detection equipment.  However, small-laboratory-scale disadvantages of many of these 
methods include calling for more than two mobile-phases (Mulinacci et al., 1999; 
Bergonzi et al., 2001; Poutaraud et al., 2001a; Avato and Guglielmi, 2004), requiring 
expensive or less-common analysis or detection equipment (Gray et al., 2000; de los 
Reyes and Koda, 2001; Tolonen et al., 2002; de Jager et al., 2004; Tatsis et al., 2007), or 
using relatively long run times (Bergonzi et al., 2001; Li and Fitzloff, 2001; Rager et al., 
2002).  A large amount of research is conducted in laboratories with only a two-pump 
HPLC system with diode array detection (DAD) and C18 column, and few methods 
match these conditions.  Some of the methods struggled to obtain sharp peaks with Hpn 
and Phn.  Ganzera et al. (2002) developed a method utilizing a less hydrophobic C12 
column to sharpen the Hpn and Phn peaks.  This method also used a two-pump/DAD 
HPLC system and was a precise method.  These authors tested several columns to find a 
column adequate for efficient SJW compound quantification.       
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SJW Antimicrobial Studies 
 
 
SJW Extractions 
Plant Parts Used in Extracts.  The aerial parts of the SJW plant have usually been 
used when authors have obtained their own plant materials for antimicrobial SJW studies 
(Gaind and Ganjoo, 1959; Avato et al., 2004).  After harvesting (and usually drying and 
grounding) the plant material, various means have been taken to prepare crude SJW 
extracts. 
Solvents and Extraction Techniques.  Solvents used in extracts have included 
MeOH, EtOH, diethyl ether (Et2O), “petrol,” chloroform (CHCl3), acetonitrile (CH3CN, 
or ACN), ethyl acetate (EtOAc), acetone ((CH3)2CO), n-butanol (C4H10O), dimethyl 
sulfoxide (DMSO), and water.  Extraction techniques using these solvents have included 
Soxhlet extraction (Barbagallo and Chisari, 1987; Avato and Guglielmi, 2004), 
sonication (Avato et al., 2004; Avato and Guglielmi, 2004), maceration (Osborn, 1943; 
Avato and Guglielmi, 2004), digestion (Avato and Guglielmi, 2004), mixing (Yesilada et 
al., 1999), and boiling with water (Reichling et al., 2001).  In a study comparing the first 
four extraction methods stated above, Avato and Guglielmi (2004) obtained the highest 
extraction efficiencies with sonication. 
 
Organisms Assayed and Results  
MIC comparisons for all organisms from the above-mentioned studies are seen in 
Table 2.1.  The organisms assayed in these studies are listed in Table 2.2.   All but the 
studies performed by Barbagallo and Chisari (1987) and Reichling et al. (2001) reported 
a much greater inhibition of Gram-positive strains than Gram-negative strains by SJW 
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extracts and compounds.  Some of these studies found that the essential oil, tanning 
agents, and Hpn were not responsible for inhibition (Neuwald and Hagenstrom, 1954; 
Gaind and Ganjoo, 1959), conflicting with the study of Avato et al. (2004), which 
showed Hpn as having antimicrobial activity.  No combination of pure compounds was 
seen in any of these studies and merits investigation.   
 
Human Alveolar Epithelial Cells (A549) 
 
 The A549 human alveolar epithelial cell line is a carcinomic, immortal cell line 
isolated from a 58-year-old man with lung cancer (Giard et al., 1973).  These cells 
contain keratin, which is useful for staining purposes (ATCC, 2009).  Due to their 
carcinomic heritage, they can be perpetually subcultured, which makes them useful for 
ongoing study.  It is also possible to measure various inflammatory markers in these cells 
in response to a treatment (Bhowmik et al., 2000).  These cells have been found to be 
relatively good models for a type of alveolar epithelial cells that are potential targets of 
macromolecule drug delivery (Foster et al., 1998).   
 A study performed by Lin et al. (1998) attempted to mimic a M. tuberculosis 
infection.  This study investigated chemokine production in response to A549 cell contact 
with M. tuberculosis cells.  It was found that only treatment with living bacteria that were 
able to achieve intracellular growth induced an inflammatory response.    
 
Summary   
In summary, MDR-TB and XDR-TB have reached a dangerous point.  Mutations 
in the genome of M. tuberculosis are making this bacterium increasingly resistant to 
chemotherapy; therefore, new TB medications are needed.  The SJW herb has shown 
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inhibitory ability for several Gram-positive bacterial strains, but previous studies have 
only included two mycobacterial isolates in SJW inhibitory assays (Table 2.2).  As the 
mycobacterial cell wall composition is different than that of other Gram-positive strains 
(it contains more mycolic acid), SJW MIC and MBC values for Gram-positive strains 
cannot be directly translated to mycobacteria.  Therefore, direct studies of the effect of 
SJW extracts and compounds on mycobacteria were performed in this research (Chapter 
4).  In order to determine inhibitory parameters, it is necessary to have accessible means 
whereby SJW compounds can be quantified.  While several SJW HPLC assays exist in 
literature, there has been a lack of an assay that utilizes a two-pump HPLC system with 
DAD detection, C18 column, and which does not take a large amount of time to 
complete; such a method was developed during the course of this study (Chapter 3).  
Finally, an effective antibiotic must not only be able to kill target bacteria, but must also 
not harm the host.  Blood Hfn levels after SJW ingestion do not reach concentrations 
above literature MIC/MBC values of assayed Gram-positive bacteria.  Therefore, other 
methods for Hfn administration, such as inhalation, merit investigation.  No study seen 
thus far has assayed for effect of SJW extracts or compounds on human alveolar 
epithelial cells (A549).  Hence, this research also investigated the effect of SJW crude 
extract and compounds on A549 viability (Chapter 5).    
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Table 2.1  Literature MIC values of SJW (except Osborn’s study, which used Hypericum 
elodes and Hypericum olympicum) extracts and pure compounds against Gram-positive 
and Gram-negative bacteria.  Gram-positive inhibition was dominant in most studies.          
 
Author(s) (Year) Extract or Pure Compound Gram(+) MIC Gram(-) MIC 
Osborn (1943)  Ground herb pulp  (in H2O) (other Hypericum) 
Not given, but inhibits No inhibition 
Neuwald & Hagenstrom 
(1954) (CH3)2CO, Pet. Ether Not given, but inhibits No inhibition 
Gaind & Ganjoo (1959) CHCl3, (CH3)2CO, EtOH  1:104-1:102 dilution No inhibition 
Gurevich, et al. (1971) Hyperforin 0.1-1.0 µg/ml 400 µg/ml 
Barbagallo & Chisari 
(1987) CHCl3, H2O, MeOH, Petrol 0.31-1.25 mg extract/ml 
1.25-2.5 mg 
extract/ml 
Schempp et al. (1999) Hyperforin 0.1-1.0 µg/ml No inhibition 
Yesilada et al. (1999) BuOH, CHCl3 7.8-250 µg extract/ml Not assayed 
Reichling et al. (2001) Boiling H2O extract 1.3-30 mg herb/ml 
15-60 or >60 mg 
herb/ml 
Avato et al. (2004) CHCl3, EtOAc, MeOH, Pet. Ether 
25-300 or >1000 µg 
extract/ml No inhibition 
 Hyperforin, Hyperforin salt 25-100 µg/ml No inhibition 
 Hypericin 12.5-25 or >1000µg/ml No inhibition 
 Flavonoids >1000 µg/ml No inhibition 
Milosevic & Solujic 
(2006) EtOH 3.5 mg extract/ml 
1.25-3.5 mg 
extract/ml 
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Table 2.2  A comprehensive list of all organisms assayed in cited SJW inhibitory assays, 
showing Gram-positive strains (left column), Gram-negative strains (center column), and 
yeasts (right column).  Corresponding authors of studies are shown in bottom right of 
table.     
 
Gram-Positives Gram-Negatives Yeasts 
Bacillus cereus i Agrobacterium tumefaciens j Aspergillus niger i 
Bacillus mycoides d,j Azotobacter chrococcum j Candida albicans d,f,h,i 
Bacillus subtilis c,d,i,j Bacillus pyocyaneus c Candida tropicalis i 
Corynebacterium diphtheriae c,f Citrobacter freundii h Cryptococcus laurentii i 
Corynebacterium michiganense d Enterobacter aerogenes h Fusarium avenaceum d 
Enterococcus faecalis d,f,h,i Enterobacter cloacae j Fusarium oxysporum j 
Listeria monocytogenes h Erwinia carotovora j Mucor plumbeus d 
MRSA h Escherichia coli a,b,c,e,f,h Penicillium chrysogenum d 
Mycobacterium phlei d Helicobacter pylori g Penicillium canescens j 
Mycobacterium tuberculosis c Klebsiella pneumoniae h,j Saccharomyces cerevisiae i 
Sarcina lutea d Proteus mirabilis h  
Staphylococcus aureus a,b,c,d,e,f,h,i Proteus vulgaris e  
Staphylococcus epidermidis h Pseudomonas fluorescens j Author(s) (Year) 
Staphylococcus oxford e Pseudomonas glycinea j a. Osborn (1943) 
Staphylococcus saprophyticus h Pseudomonas phaseolicola j b. Neuwald & Hagenstrom (1954) 
Streptococcus agalactiae f Pseudomonas aeruginosa e,f,h c. Gaind & Ganjoo (1959) 
Streptococcus haemolyticus c Salmonella choleraesuis h d. Gurevich et al. (1971) 
Streptococcus mutans e Salmonella paratyphi A c e. Barbagallo & Chisari (1987) 
Streptococcus pyogenes f,h Salmonella paratyphi B c f. Schempp et al. (1999) 
Streptococcus sanguis e Salmonella typhi b,c g. Yesilada et al. (1999) 
Streptococcus viridans c Shigella dysenteriae c h. Reichling et al. (2001) 
 Shigella flexneri h i. Avato et al. (2004) 
 Vibrio cholerae c j. Milosevic & Solujic (2006) 
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Figure 2.1  Chemical structures of Hpn (a), Phn (b), and Hfn (c) (Bauer et al., 2001). 
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CHAPTER 3 
 
HPLC-DAD QUANTIFICATION OF SJW COMPOUNDS 
 
 
Introduction  
 
Compounds in the SJW herb are of interest to the medical community for their 
antidepressant, antibiotic, anticancer, antiviral, and anti-inflammatory activity.  A simple 
high-performance liquid chromatography (HPLC) method was developed during the 
course of these studies that uses common HPLC separation and analysis equipment for 
the quantification of pseudohypericin (Phn), hyperforin (Hfn), and hypericin (Hpn).  This 
30-min method requires only two mobile phases, a multi-wavelength UV/VIS detector 
(such as photodiode array), and a C18 column.  The concentrations of the three 
compounds in the methanol (MeOH) SJW extract were determined.  This method is 
particularly useful for laboratories that do not have the more expensive equipment called 
for by many SJW HPLC analytical protocols.      
 
Materials and Methods 
 
 
Acidified MeOH Preparation 
 
Acidified MeOH, pH 2.5, was prepared using 85% phosphoric acid (H3PO4, 
Mallinckrodt Chemicals, Phillipsburg, NJ) (de los Reyes and Koda, 2001).  The pH was 
lowered dropwise with a 9” glass Pasteur pipette (Fisherbrand, Fisher, Pittsburgh, PA).  
Previously, volume dispensation of this pipette was measured using a laboratory balance 
and dividing the average mass of 30 drops of acid by its density (1.685 g/ml for 85% 
H3PO4) to obtain an average of 17.98 µL of 85% H3PO4 per drop.  A glass pH probe 
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calibrated using aqueous buffers was used to determine that 11 drops per 250 ml MeOH 
(Fisher Chemicals, Pittsburgh, PA), or a solution of 0.079% (v/v) H3PO4, brought the 
measured pH to 2.5.  Oxygen was then removed by sparging with nitrogen for 
approximately 10 min.  Evaporation was minimized by capping the bottle with Parafilm 
that had a small puncture for gas escape.   
 
SJW Crude Extract and Pure Compound  
Preparation 
 
SJW crude extract preparations were performed in low-intensity green filtered-
light using a headlamp (Quad Tactical LED, Princeton Tec, Trenton, NJ) with 
wavelength emissions above the degradation ranges (400 nm) (Figure 3.1).  Hfn, Hpn, 
and Phn standards (Enzo Life Sciences, Plymouth Meeting, PA) were brought to 
concentrations of 4000 µg/ml by adding acidified MeOH with syringes.  These were 
stored in 1-ml amber glass crimp vials (Fisherbrand, Fisher, Pittsburgh, PA) at -20˚C.   
SJW powder used for making the crude extract was prepared by grinding the 
contents of SJW capsules (GNC, Pittsburgh, PA) to a fine powder using a mortar and 
pestle and storing at 4˚C.  A “1X” MeOH extract was prepared by adding 30 ml acidified 
MeOH to 10.8 g SJW powder in a 50-ml centrifuge tube (Corning, Corning, NY).  A 
“2X” extract was similarly prepared by adding 15 ml acidified MeOH to 10.8 g SJW 
powder.  The contents were mixed by vortexing and shaking and stored at room 
temperature overnight.  After vortexing and shaking again the next day, the mixtures 
were centrifuged for 10 min at 4000 RPM (3452 RCF).  The supernatant was 0.2-µm 
filtered and stored in a 10-ml amber glass vial at -20˚C. 
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Determination of Herb Volume, Porosity, 
and Extract Concentrations 
 
Specific herb volume was determined by adding 30 ml acidified MeOH to 10.8 g 
of SJW powder, mixing thoroughly, and dividing the volume increase by herb mass.  
Porosity was determined using equation 1.  The void volume (VV) was the difference of 
the dry herb volume (VT) and the true (wet) volume.   
€ 
Porosity = VVVT
   (1)  
Extract masses of the 2X and 1X SJW solutions were determined by measuring the dry 
weight of 1-ml (in triplicate) of these extracts.  This was done by subtracting the 
premeasured mass of the weigh boats from the oven-dried (60ºC) extracts after two days 
and averaging the triplicate for each extract.  Using a scale, it was determined that a 1-ml 
syringe (BD, Franklin Lakes, NJ) was more accurate for dispensing this organic solution 
than a pipette with plastic tip, even after wetting the tip.   
 
SJW Solubility Testing  
Preliminary HPLC work revealed problems with precipitation of organic SJW 
extract in the mobile phase, causing clogging of the pre-column.  Therefore, a solubility 
test was devised to determine the solubility ranges of SJW MeOH extract in the common 
HPLC solvents MeOH and acetonitrile (ACN) (Honeywell Burdick & Jackson, West 
Chester, PA).  Aqueous concentrations of these solvents were prepared from 0-100% 
(v/v) in 10% increments.  1X SJW MeOH extract was then added at a 2% (v/v) 
concentration.  Optical density measurements at 600 nm (OD600) were taken to determine 
maximum solubility ranges of SJW MeOH extract in these solvents.   
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HPLC Analysis 
 
Mobile Phase Preparation.  Mobile phase A was 80:20 acetonitrile:water and 
0.035% (v/v) 85% H3PO4.  Mobile phase B was 99:1 acetonitrile:water and 0.035% (v/v) 
85% H3PO4.  Degassing was performed using a Fisher Scientific sonicator (FS60, Fisher, 
Pittsburgh, PA) for 45 min, with bottles wrapped in Parafilm punctured with small holes 
to allow gas escape. 
Line and Pump Priming.  Line and pump priming was achieved by pulling 10 ml 
through the tubing, discarding, then pulling another 10 ml through the tubing and using 
this to prime each respective pump.  The detector and pumps were run for 10 min (with 
the pumps at 50:50 A:B at 0.5 ml/min), after which a blank run was performed to clean 
the column and run the pumps at higher flow rates.   
HPLC Method.  The HPLC instrument used was a Beckman System Gold model 
125S equipped with a 168 photodiode array (or simply “diode array”) detector (DAD).  
Injection volume was 60 µl into a 20 µl loop to compensate for laminar flow issues and 
done at a rate of approximately 5 µl/s.  To prevent column overloading when analyzing 
the crude extract, a 1:50 dilution (2% v/v) was used (this volume was also used most 
commonly in the SJW inhibitory studies).  The HPLC method was as follows: at 0 min 
100:0 A:B at 1.5 ml/min; at 8 min a 0.5-min flow rate increase to 2.5 ml/min; at 11 min a 
0.5-min flow rate decrease to 1.5 ml/min and a 1-min A-B gradient to 0:100 A:B; at 16 
min a 0.5-min flow rate increase to 2.5 ml/min; and at 28 min a 0.5-min flow rate 
decrease to 1.5 ml/min and a 1-min B-A gradient to100:0 A:B to equilibrate the column 
in preparation for the next run.  The method ended at 30 min.   
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Loop and Injector Cleaning.  Loop and injector cleanings between runs were done 
by flushing 1 ml of mobile phase A using a 1-ml blunt-end syringe with a Parafilm 
wrapping around the needle to allow for sealing against the injection port.  Some cleaning 
solution was allowed to flow backwards out from the port to clean the port entrance.  
Sample injection syringe cleaning was done using several (usually three) EtOH rinses 
followed by several acidified MeOH rinses.   
Peak Analysis and Preparation of Calibration Curves.  Analysis of peak area was 
performed using the Gold Noveau integration software with absorbance readings taken at 
the following wavelengths: Phn: 590 nm; Hfn: 273 nm; Hpn: 578 nm.  Threshold and 
peak width settings had to be changed from time to time, especially for the hypericins, to 
cause the peak integration baseline to span the bottom of the peak.     
Calibration curves were prepared through selection of the most accurate and 
precise of three calibration curves prepared for each of the three active compounds.  The 
calibration curves for Phn and Hpn consisted of five points (as these were more difficult 
to quantify) in singlet, while the calibration curve for Hfn consisted of four points in 
duplicate.  Final Phn and Hpn calibration curves spanned concentrations from 12.5-100 
µg/ml, and the final Hfn calibration curve spanned concentrations from 5-100 µg/ml.  
The three compounds were usually mixed together and analyzed simultaneously, 
allowing for more efficient calibration curve preparation.  Acidified MeOH was the 
diluent used to prepare the solutions. 
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Repeatability Testing 
 
Three sets of calibration curves allowed for the investigation of the repeatability 
of this method.  Repeatability was determined by investigating the variation between sets 
of regression equations for each compound, given a certain area.   
 
Determination of Active Compound 
Photoconversion or Photodegradation 
 
 Photoconversion/photodegradation of SJW compounds were investigated by 
preparing a fresh 10-ml amber glass vial of 1X SJW extract and placing it in a New 
Brunswick Scientific Innova 42 photosynthetic incubator-shaker, shaking approximately 
5 cm beneath the photosynthetic light at a photon irradiance of 223 µmole/m2/s/nm.  The 
spectrum and light intensity of this incubator are shown in Figures 3.2 and 3.3, 
respectively, with the spectrum almost completely above 400 nm.  Samples (250 µl each) 
were taken from the vial at times 0, 15 min, 30 min, 1 hr, and 2 hr, and active compound 
concentrations were analyzed using the regression equations from the calibration curves.   
 
Results and Discussion  
 
 
Herb Volume, Porosity, and  
Extract Concentrations 
 
Wet (true) and dry volumes and porosity of the ground SJW herb, as well as 
concentrations of the extract, are given in Table 3.1.  It can be seen from these values that 
the MeOH dissolved a substantial part of the herbal mass (46.1% for 1X and 46.5% for 
2X).  Hence, about 46% of the herb mass is soluble in MeOH using the extract 
preparation methods outlined above.  Though the MeOH volume added for the 1X 
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solution was twice the volume as the MeOH added for the 2X solution, to the same mass 
of SJW herb, this did not double the 1X solution volume (as the herb itself occupies 
considerable volume at these concentrations).  The 1X solution had a 67% higher volume 
than the 2X solution.  The 2X extract had approximately the same percentage greater 
measured mass (68%) than the 1X extract.  If the 2X extract had been saturated, its 
percentage mass increase (compared to 1X) would have been less than the percentage 
volume increase of 1X.  Therefore, these results show that the 2X extract had not reached 
the solubility limit of SJW in MeOH.  The extracts were observed qualitatively to have a 
high viscosity and a dark, tar-like appearance, even after filtering through a 0.22 µm 
filter. 
 
SJW Solubility 
 The OD600 data for SJW MeOH extract solubility in MeOH and ACN is shown in 
Figure 3.4.  Greatest solubility was found to be at values greater than 70% MeOH or 
between 60-80% ACN.  It was found that if the beginning mobile phase was outside of 
the SJW solubility range, it caused analyte precipitation and clogging in the pre-column.  
Therefore, the “A” mobile phase of 80% ACN(aq) was found to be effective at quickly 
eluting the non-targeted polar compounds.  By using this mobile phase isocratically for 
the first 10 min of the run, it also provided clear resolution of compounds through the 
elution of Phn.  Afterward, there was no precipitation as the gradient moved to 99% 
ACN. 
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Chromatograms, HPLC Parameters, and  
Standard Curves 
 
Typical chromatograms for the Phn, Hfn, and Hpn standards are shown in Figure 
3.5, and their corresponding crude extract chromatograms are given in Figure 3.6.  
Calibration curves for these compounds are shown in Figure 3.7.  Retention time ranges, 
regression equations from the calibration curves, and correlation coefficients are shown 
in Table 3.2.  Compound concentrations in a 1:50 dilution of the 1X extract are shown in 
Table 3.3.  It should be noted that as the concentrations of the hypericins increased, the 
retention times decreased; therefore, there were small time ranges for the retention times 
of these compounds.  Also, though formal limit of detection (LOD) tests were not 
performed, the hypericins were generally difficult to detect at concentrations lower than 
25 µg/ml.  Hfn was easily detectable at all concentrations attempted.  The lowest 
attempted concentration of Hfn was 1 µg/ml, which produced a sharp, easily integratable 
peak, so lower concentrations of this analyte should also be integratable.  Figure 3.8 
shows a contour view of the DAD data for a typical crude extract HPLC run, with X-axis 
time, Y-axis wavelength, and Z-axis (coming toward the viewer) milli-arbitrary (or 
absorbance) units (mAU), which has magnitude marked by color.  Magnitude color 
indicators (from highest to lowest) are red, yellow, green, light blue, dark blue, and 
purple.  Analysis was performed at 590 nm for Phn, 273 nm for Hfn, and 578 nm for 
Hpn.  This view shows the numerous compounds in SJW that are able to be effectively 
resolved using this HPLC method. 
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Repeatability 
 This method was found to be highly repeatable for Hfn and less repeatable for 
Phn and Hpn, as shown in the compound concentration values from each calibration 
curve, along with their means and standard deviations, in Table 3.3.  As the standards 
used in the creation of both the method and the first set of calibration curves were 
somewhat old (six weeks) and returned relatively imprecise values for the hypericins, it 
was decided to not make the first set the official calibration curves for this method.   
The second and third calibration curve regression equations for Phn and Hfn 
returned concentration values within 2% of each other.  It was decided to use the 
regression equation from third calibration curve for Hfn, as the four points in this 
calibration curve came from duplicate analysis using fresh stock solution.  The regression 
equations from the second set of standard curves were used for the hypericins; even 
though these calibration curves were performed in singlet, they each consisted of five 
points (as opposed to three points in the third set due to difficulty in integrating 
concentrations below 25 µg/ml), produced higher correlation coefficients, and were 
prepared with fresh stock solution.  The Hpn calibration curve used successfully 
integrated peaks at 5 µg/ml and 10 µg /ml, which was another reason it was used.   
 
Photoconversion/Photodegradation  
of Active Compounds 
 
 Normalized concentration data for the three SJW analytes after exposure to the 
Innova photosynthetic light are shown in Figure 3.9.  There was a 20% increase in Phn, a 
4% decrease in Hpn, and a 41% decrease in Hfn.  The loss in Hfn was considered to not 
be worth the relatively small photoconversion-gain in Phn, so photoconversion was not 
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carried out in any additional experiments.  These novel results show degradation of Hfn 
at wavelengths above 400 nm, contrary to reported values on the subject (Ruckert et al., 
2007). 
 
Discussion     
As the use of MeOH in HPLC analysis is often preferred due to its relatively low 
cost, several attempts were made to use this solvent in our analysis.  However, this 
solvent did not have the hydrophobicity necessary to elute the highly nonpolar Hpn 
within the target 30-min timeframe.  Also, the primary purpose of this HPLC method is 
for efficient analysis, not preparative purposes, and does not use an exorbitant amount of 
solvent.  Therefore, the benefits outweigh the drawbacks in the use of ACN along with 
MeOH.    
The development of a 30-min SJW HPLC quantification method with a C18 
column for Phn, Hfn, and Hpn proved to be a difficult task.  This was primarily due to the 
chemical properties of the hypericins, which caused relatively wide peak bases, tailing, 
and in the case of Hpn, a long retention time.  To narrow the Phn and Hpn peaks in this 
method, flow rates were increased from 1.5 ml/min to 2.5 ml/min during the elution of 
both of these peaks.  Though less hydrophobic columns, such as a C8 or C12 column, are 
able to provide a sharper peak shape for the hypericins, the C18 column is more common, 
and that is why this method was developed.  However, the less hydrophobic column is 
recommended if available, in which case a different method would have to be used (such 
as that outlined by Ganzera et al., 2002). 
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It was also determined that injecting three times the sample loop volume helped to 
overcome laminar flow issues and purge the mobile phase from the loop, thereby 
injecting a pure 20 µl of sample into the column.  It was found that this allowed for 
greater consistency in peak area, as shown by the relatively high correlation coefficients.  
It was also found that if there was not enough analyte volume to inject three times the 
loop volume, a very slow injection of a smaller volume could also achieve consistency.     
The last part of the HPLC method goes through an equilibration phase to prepare 
the column for the next run, which can be started immediately should the need exist.  
After preparing this method initially, the HPLC run time was allowed to go far beyond 30 
min to ensure that Hpn was the last SJW compound to exit the column, which it was.  
Therefore, this method allows for the user to immediately begin another run.  
  
Conclusions  
 
A SJW HPLC method for the quantification of Phn, Hfn, and Hpn within 30 min 
has been developed and shown to be effective.  This method requires only two mobile 
phases, a UV/VIS detector (such as photodiode array), and a C18 column.  It also avoids 
clogging of the extract in the precolumn.  While this method may be used for the 
quantification of Phn and Hpn, it is most accurate and repeatable for the quantification of 
Hfn.  It has been found that wide Phn and Hpn peaks is a common problem in C18 
column analysis of SJW, and for increased accuracy in their analysis, a method utilizing a 
less hydrophobic column is recommended.  The biggest advantage of our method is for 
researchers who are interested in investigating SJW who only have access to the most 
common HPLC separation and detection equipment.   
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Table 3.1  Volumes, concentrations, and porosity of SJW herb and MeOH extract.  Only 
the 2X and 1X extracts were assayed using HPLC.  The other dilutions are dilutions of 
the 1X extract and are listed for reference for other chapters (usually added to cultures at 
1:50 dilutions).  SJW extract concentration is mg solids, not solution, per ml.  
  
SJW	  Herb	   Wet	  volume	  (ml/g)	   Dry	  volume	  (ml/g)	   Porosity	  
Ground	  Herb	   0.694	   1.39	   0.501	  
SJW	  Extract	   mg	  herb/ml	  solvent	   mg	  herb/ml	  solution	   mg	  extract/ml	  solution	  
2X	   720	   480	   223	  
1X	   360	   288	   133	  
1/2X	   180	   144	   67	  
1/4X	   90	   72	   33	  
1/8X	   45	   36	   17	  
1/16X	   23	   18	   8	  
	  
	  
Table 3.2  Retention times, regression equations, and correlation coefficients (R2) for the 
three SJW analytes from 1:50 dilutions of SJW extract.  The regression equations came 
from the second set of calibration curves for Phn and Hpn and from the third set for Hfn. 
 
Parameter	   Pseudohypericin	   Hyperforin	   Hypericin	  
Retention	  time	   10-­‐10.5	  min	   15	  min	   22.5-­‐23.5	  min	  
Regression	  equation	   Y=1419.9x-­‐3739	   Y=10553x-­‐1063.2	   Y=5100.1X-­‐6667.2	  
Correlation	  coefficient	   0.996	   0.999	   0.995	  
 
 
Table 3.3  Assayed concentration values of SJW compounds at 1:50 dilution of the 1X 
crude extract.  Three sets of calibration curves were prepared for Phn and Hfn, and two 
were prepared for Hpn to test repeatability.  The second sets of calibration curves were 
used for Phn and Hpn, and the third set was used for Hfn.  Compound concentrations are 
listed at this dilution for ease in comparison with the inhibitory studies in Chapters 4 and 
5, as this is the most common concentration (v/v) that the crude extract was added to 
cultures.      
 
Cal.	  Curve	  Set	   Pseudohypericin	  (µg/ml)	   Hyperforin	  (µg/ml)	   Hypericin	  (µg/ml)	  
1	   34.4	   43.3	   26.4	  
2	   53.4	   46.2	   15.4	  
3	   54.4	   45.5	   NA	  
Mean	   47.4	   45	   20.9	  
Std.	  Deviation	   11.3	   1.5	   7.8	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Figure 3.1  Normalized spectra of filtered-light headlamp used when working with light-
sensitive compounds. The green filter was mostly used, as its emission corresponded with 
the photoconversion (from their protoforms) wavelengths of the hypericins (510-540 nm) 
and prevented Hfn degradation, which occurs below 400 nm (Poutaraud et al., 2001b).   
 
Figure 3.2  Spectrogram of the Innova incubator-shaker photosynthetic light.  Very little 
emission is seen below 400 nm (Hfn-damaging wavelengths). 
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Figure 3.3  Photon irradiance of the Innova incubator-shaker photosynthetic light as a 
function of distance from the light source.  The photoconversion/photodegradation 
experiment was carried out at a distance of 5 cm with a photon irradiance of  
223 µmol/m2/s/nm.   
 
Figure 3.4  Solubility (OD600) of 2% (v/v) SJW crude MeOH extract in various aqueous 
concentrations of MeOH and ACN.  Lower OD equals higher solubility.  The crude 
extract had highest solubility at concentrations of ≥ 70% MeOH or 60-80% ACN.   
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Figure 3.5  Typical chromatograms for Phn, Hfn, and Hpn standards, with retention 
times of approximately 10, 15, and 22.5 min, respectively.  The 273 nm chromatogram 
for Hfn is below (blue), and the 590 nm chromatogram for the hypericins is above (red).   
 
Figure 3.6  Typical chromatograms for Phn, Hfn, and Hpn in 1:50 dilution of 1X (2.66 
mg extract/ml) crude extract, with retention times of approximately 10.5, 15, and 23.5 
min, respectively. The 273 nm chromatogram for Hfn is below (blue), and the 590 nm 
chromatogram for the hypericins is above (red).  
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Figure 3.7  Calibration curves used in the quantification of SJW compounds.  The Hfn 
curve had the highest correlation coefficient, followed by Phn, then by Hpn.  The Hfn 
calibration curve shown was the third curve prepared for this compound, and the 
hypericins were each their second calibration curves prepared. 
 
Figure 3.8  Contour view of HPLC mAU data for SJW crude extract.  X-axis is time 
(min), Y-axis is wavelength (nm), and Z-axis (coming toward the viewer) is absorbance 
(mAU).  Red represents highest absorbance, followed by yellow, green, light blue, dark 
blue, and purple.   
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Figure 3.9  Photoconversion/photodegradation study of SJW compounds.  A 20% 
concentration increase was observed in Phn, a negligible concentration change was 
observed in Hpn, and a 40% concentration decrease was observed in Hfn.  While Ruckert 
et al. (2007) state that Hfn degradation occurs at wavelengths below 400 nm, these 
findings show significant Hfn degradation above 400 nm. 
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CHAPTER 4 
 
EFFECT OF HYPERICUM PERFORATUM ON MYCOBACTERIA VIABILITY 
 
 
Introduction 
 
 Of all the literature reviewed, only two Mycobacterium strains, one time each, 
have been included in SJW inhibitory/bactericidal assays.  This is an insufficient sample 
size if one is to understand the response of this genus to SJW extracts and compounds.  
To create a larger data set on the response of mycobacteria to SJW, seven nonpathogenic 
mycobacteria (six of which are the only genetically sequenced nonpathogenic 
Mycobacterium strains currently available) were used in a series of inhibitory and 
bactericidal studies presented here.  These strains contain as much as 72% homology to 
the M. tuberculosis genome (see Figure 4.1 for a Venn diagram comparison of these 
genomes).  With these results, investigators should be able to better predict how 
pathogenic mycobacteria might respond to the SJW herb.   
 
Materials and Methods 
 
 
Comparison of Mycobacterial Genomes 
 
 Mycobacterial genomes were compared using the Integrated Microbial Genomes 
(IMG) section of the Department of Energy (DOE) Joint Genome Institute (JGI) website 
(www.jgi.doe.gov).  Under the menus “Find Genes,” “Phylogenetic Profilers,” “Single 
Genes,” the “Find Genes In” option was selected for M. gilvum PYR-GCK, and the 
“With Homologs In” option was selected for all nonpathogenic Mycobacterium isolates 
and for M. tuberculosis CDC1551.  Similarity cutoffs were as follows: Max. E-value: 1e-
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5, Min. Percent Identity: 30, Exclude Pseudo Genes: No, Algorithm: By Present/Absent 
Homologs, Min. Taxon Percent With Homologs: 100, Min. Taxon Percent Without 
Homologs: 100.    
 
SJW Extract and Pure Compound  
Preparation 
 
SJW extracts and pure compound solutions were prepared in the manner outlined 
in Chapter 3.  The solvent used for preparing SJW extracts in most of the inhibitory 
studies was MeOH.  However, acetone, ethanol, ethyl acetate, chloroform, and water 
were also used for a study comparing the inhibition of SJW extracts of different solvents.  
SJW from GNC (Pittsburgh, PA) was used for most studies.  However, the Nature’s Way 
(Springville, UT) and NOW (Bloomingdale, IL) brands of SJW were also used in a study 
comparing SJW brands.  Extracts used in the earliest studies were not 0.2-µm filtered, but 
nearly all studies used filtered extract.  Dilutions of the crude extract were made by 
diluting the 1X, not 2X, stock solution (Table 3.1).   
 
Media Preparation 
 Luria broth (LB) and agar, as well as Middlebrook broth (MB) and agar, were 
prepared according to protocols in the Appendix.  Ampicillin was added to the media for 
one study comparing growth with and without it and was added from stock solution to a 
working concentration of 50 µg/ml.  Tween 80 (Sigma, St. Louis, MO) was often added 
at a 0.5% (v/v) concentration of a 10% (w/v) stock solution, making a working 
concentration of 0.05%.    
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Culture Preparation 
Cultures and Growth Conditions Used.  The Mycobacterium cultures used for the 
inhibitory/bactericidal studies were M. JLS, M. KMS, and M. MCS (isolates from Utah 
State University), M. smegmatis (#14468, ATCC, Manassas, VA), M. phlei (ATCC 
#BAA-486), and M. vanbaalenii PYR-1 and M. gilvum PYR-GCK (isolates obtained 
through a combined Joint Genome Institute sequencing effort).  Gram-negative controls 
were Pseudomonas putida (obtained on USU campus) and Escherichia coli (ATCC 
#25922).  The Gram-positive control was Bacillus subtilis (ATCC #6051).  A qualitative 
study was performed that compared the growth of mycobacteria on LB and MB media, 
and LB media was used for all other studies.  All cultures were incubated at 37°C except 
for B. subtilis, which was incubated at 30°C.  Broth cultures were incubated in shaking 
conditions at 220 RPM for 12-ml culture tubes (BD Falcon, Franklin Lakes, NJ) or 150 
RPM for 48-well plates (BD Falcon, Franklin Lakes, NJ).   
Freezer Stock Preparation.   Freezer stocks of the bacterial isolates were prepared 
by adding 500 µl of turbid culture to 500 µl of 30% (v/v)(aq) sterile glycerol, bringing the 
final cell solution to 15% (v/v) glycerol, in a 1.5 ml microcentrifuge tube (Fisher, 
Pittsburgh, PA).  This was kept at -80ºC.   
 Broth Culture Preparation.  Broth cultures were inoculated by adding a volume 
of bacterial freezer stock (typically between 50-200 µl, with more volume for shorter 
time to turbidity) to liquid media.   Inoculations were typically done in 5 ml media in 12-
ml culture tubes.  At the beginning of experiments, cultures were diluted with LB media 
in a 50-ml centrifuge tube (Corning, Corning, NY) (typically about a 1:100 dilution) to an 
optical density (OD600) of between 0.01-0.05 using a spectrophotometer (Bio-Spec Mini 
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00834, Shimadzu, Columbia, MD).  If Tween 80 was to be added, it was also done at this 
time prior to dispensing the inoculated media into the assay containers, which were either 
12-ml culture tubes or 48-well plates.   
 Agar Plate Culture Preparation.  Agar plate cultures were prepared either for 
working culture storage or for SJW inhibitory assays.  For streak plates, a small amount 
of bacteria was streaked in small portion of the plate along the edge (about 1/5 of the 
plate).  This first section required either a small volume (5-10 µl) of liquid culture or a 
small amount (barely visible on a pipette tip) of bacteria from another plate.  Using a 
pipette tip (usually a 1.5-ml tip), this section of the plate was then streaked over to the 
next 1/5 of the plate using a new tip.  This process was repeated, each time using a new 
tip, until all sections of the plate had been streaked.  If several strains were used on one 
plate, then the plate was divided into sections, and each strain was streaked only in its 
section.   
 
Culture Treatment 
 Inhibitory Assays.  Inhibitory assays (not bactericidal assays) were performed on 
SJW-containing agar plates.  These studies used plates that had SJW crude extract or 
solvent (for controls) added to the plates at their coolest point before solidification.  The 
plates were then swirled to mix and allowed to solidify before treating with cultures.  
Crude extract was added at equal concentrations for a study comparing inhibition of three 
different SJW brands and extracts of six different solvents, and it was added at different 
various concentrations for a study investigating MIC values.  Plates with no growth were 
above the minimal inhibitory concentration (MIC), and plates with growth were below it.  
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When pipetting SJW crude extract solution or organic solvents, greater accuracy was 
achieved by “wetting” the tip, pipetting up and down once or twice before the final 
aspiration and dispensing.  Pipetting accuracy was measured using a laboratory scale to 
verify accurate weight using the solvent density.     
 Bactericidal Assays.  Bactericidal assays were performed in SJW-containing broth 
media.  After culture preparation, SJW crude extract or pure compounds were added to 
the cultures at various concentrations in low-intensity green-filtered-light conditions.  
Crude extract studies were carried out in culture tubes (except when used for comparison 
in the pure compounds MBC studies, in which case a 48-well plate was used), while pure 
compound studies were carried out in 48-well plates (except for one study comparing the 
effect of light exposure on Hfn inhibition of M. KMS, in which case 12-ml culture tubes 
were used).  For accurate dispensing of volumes, syringes were used to dispense the SJW 
treatments.  For volumes between 250-1000 µl, a 1-ml graduated syringe (BD, Franklin 
Lakes, NJ) was used.  For volumes less than 250 µl, graduated glass syringes were used 
(Hamilton, Reno, NV).  After EtOH/MeOH toxicity studies, SJW crude extract and pure 
compounds were added at concentrations at or below 2% (v/v).  Cultures were then kept 
at the appropriate temperature (stated above), and cell samples were taken at various time 
points for cell counting (method outlined below). 
 Effect of Tween 80 on Hfn MBC Study.  A study investigating the effect of various 
concentrations of Tween 80 on Hfn MBC was performed using M. JLS as a 
mycobacterial representative.  Cultures containing six concentrations of Tween 80 (2-fold 
dilutions) were added to a 48-well plate in triplicate and all treated with the same Hfn 
concentration of 46 µg/ml.  A no-Tween 80 control, as well as a no-Tween 80/Hfn 
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control, were included.  CFU counts were taken each day for 3 days, with the first CFU 
count taken before Hfn addition.       
 
Colony Forming Unit (CFU) Quantification- 
Cell Dilution Method 
 The cell dilution method was by performed by doing the following: in a 96-well 
Costar plate (Fisher, Pittsburgh, PA), 90 µl of LB media was placed in columns 2-8 using 
an Eppendorf eight-channel pipette (Fisher, Pittsburgh, PA) with Eppendorf ep tips 
(Fisher, Pittsburgh, PA).   After thoroughly resuspending a cell culture using a larger 
pipette, 30 µl were taken and placed into a well in column 1.  After column 1 had been 
filled with samples from eight cultures, the multichannel pipette was used to perform 
serial dilutions, changing tips between each column.  Minor but important techniques 
included the following: (1) ensuring a tight fit of the pipette tips on the pipette; (2) 
thoroughly mixing the contents of the wells in each column before transferring to the next 
column (via stirring and pipetting up and down several times with the pipette tips); (3) 
keeping the tips off the bottom of the wells to avoid sudden aspiration (which leads to 
excessive volumes); and (4) visually inspecting the tips for precision and to ensure the 
presence of solution in the tips before transferring to the next column.   
 Each cell dilution was spotted on an antibiotic-free LB agar plate.  Blowing out 
with the pipette when applying spots to a plate was avoided due to spraying when the 
bubble in the spot burst, which would cause rogue colonies and less-accurate CFU 
counts.  Instead, pipette volume was adjusted to slightly higher (0.5 µl higher) than 
desired dispensing volume (10 µl) to compensate for the volume not dispensed from not 
blowing out.  After securing four pipette tips on the pipette, the four most dilute wells in 
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a row of the 96-well plate were thoroughly mixed, and four spots were placed on the 
plate.  Uniform spots were obtained by slowly dispensing the liquid (forming droplets on 
the tips) and slowly lowering the drops to the surface (touching the media with the tips 
was avoided, as spraying could occur with pressure build-up if the tip was touching the 
agar).  Without changing tips, the four most concentrated wells in the same row were 
then thoroughly mixed and placed on the agar plate in the same manner.  The plates were 
allowed to sit in the laminar flow hood until the spots absorbed into the media (about 30-
45 min), after which they were wrapped in Parafilm and placed in an incubator (37ºC for 
all strains except for B. subtilis and E. coli, which were incubated at room temperature 
due to their higher growth rates).   
 After visual colony growth on the plates (about four to five days for mycobacteria 
and one day for E. coli and B. subtilis), colonies were counted.  Two counts were taken 
from the two spots that had the highest number of countable colonies.  These values were 
then back-calculated to yield CFU/10 µl, then multiplied by 100 to yield CFU/ml.  The 
two CFU counts from each plate were averaged as the final CFU count, with the error 
being the standard deviation.  A “time 0” count was always taken, usually before the 
addition of SJW crude extract or compounds, followed by additional counts at various 
time points.   
 
Scanning Electron Microscopy (SEM) Cell  
Fixing 
 Scanning electron microscopy (SEM) imaging was performed for all the strains 
without SJW treatment, and imaging was performed for M. KMS, M. smegmatis, B. 
subtilis, and E. coli after treatment with the crude extract at various concentrations and 
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time points.  Cell fixation and imaging procedures were performed by Dr. TC Shen and 
Dr. FenAnn Shen of the USU Physics Department.  Cell fixation protocols are in the 
Appendix. 
 
Results and Discussion 
 
 
Comparison of Mycobacterial Genomes 
 Homology comparisons of all nonpathogenic Mycobacterium genomes with M. 
tuberculosis are shown as a Venn diagram in Figure 4.1.  The outer, non-percentage 
numbers indicate number of genes.  The outer percentages indicate percent genes unique 
to each isolate.  Middle percentages indicate percent genes shared with M. tuberculosis.  
Inner percentages indicate percent genes of M. tuberculosis that are incorporated into 
each isolate, which is of greatest interest for this study.  Percent M. tuberculosis genome 
incorporation is as follows (from greatest to least): M. MCS (72%), M. smegmatis (69%), 
M. KMS (69%), M. vanbaalenii (67%), M. JLS (66%), and M. gilvum (65%).  This 
comparison sheds greater light on the selection of organism for a M. tuberculosis 
surrogate.  M. smegmatis is commonly used as a pathogenic surrogate, but for 
tuberculosis studies, perhaps  M. MCS would be a more appropriate choice, with three 
percentage points greater similarity.  M. MCS was found to have the greatest morphology 
similarity to M. smegmatis out of all assayed isolates from these studies; colonies from 
these isolates were found to grow more laterally and have a more “dry” appearance on an 
agar plate than other isolates, and there was a higher degree of cell clumping in liquid 
culture than other isolates.  The high degree of clumping of these two isolates did make 
CFU quantitation difficult, however.  Therefore, isolates that exhibited less clumping, 
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such as M. JLS or M. KMS, were often chosen to act as mycobacterial representatives in 
studies requiring many samples that could only accommodate one or two strains.  The 
isolates assayed the most through these studies are shown in Figure 4.2: M. JLS, M. 
KMS, M. MCS, M. smegmatis, and M. phlei.   
 
Demonstration of Inhibitory Effect of 
Extracts of Different Solvents and  
Different SJW Brands 
 
 The inhibition/growth results of M. JLS, M. KMS, M. MCS, M. vanbaalenii, M. 
gilvum, and Gram-negative-control Pseudomonas putida control after one week and two 
weeks are shown in Tables 4.1 and 4.2, respectively.  Plates where fungal contamination 
occurred (as this study did not use filtered crude extract) are denoted as “not determined” 
(ND).  Growth inhibition occurred in all organic extracts of SJW, with the exception of 
the Nature’s Way chloroform extract; plates with this SJW brand showed growth of M. 
gilvum PYR-GCK in the ethyl acetate plate and growth of all strains except M. 
vanbaalenii PYR-1 in the chloroform plate.  The cause for this is uncertain, though 
settling of the relatively high-density chloroform (specific gravity 1.48) may have had an 
effect.  No inhibition occurred in any plates containing water SJW extract except the 
GNC M. MCS plate.  The results show very little differences between the different brands 
of SJW and between different types of organic extracts.  As GNC SJW was easy to obtain 
and showed the least amount of fungal contamination, and since MeOH was the most 
commonly used solvent in other SJW studies in literature, GNC SJW and MeOH were 
used for the remaining studies.  Images of the GNC plates for each type of solvent, along 
with the controls, are shown in Figure 4.3.   
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 It is interesting to note the pigmentation differences between the extracts of the 
various solvents.  The dark pigmentation caused problems in colorimetric assays 
throughout the study (i.e., spectrophotometric growth assessment or protein assay).  The 
ethyl acetate extract was much less pigmented in media than the others yet still inhibited 
mycobacterial growth.  Hence, future studies may warrant the use of the ethyl acetate 
extract and LB media to reduce pigmentation and make colorimetric/spectrophotometric 
assays a more viable option.    
 
Comparison of Mycobacterial Growth on  
Different Media Types 
 
While no significant difference was seen in cell growth on LB or MB media, there 
was significant difference seen in cell pigmentation, particularly in the USU isolates M. 
JLS, M. KMS, and M. MCS (Figure 4.4).  The LB plates produced cells with a deeper 
yellow pigmentation, making them easier to see.  Due to the easier visibility of the cells 
on LB, the relative ease of making this media, and its lower cost, it was decided to use 
LB media for the remainder of this study.    
 
Ampicillin Resistance of Mycobacteria 
 
The effect of ampicillin (50 µg/ml) on the growth of the five mycobacterial 
isolates is shown in Figure 4.5.  While there was not a dramatic visual difference in cell 
growth, the ampicillin did have an effect on cell pigmentation; the cause for this is 
unknown.  As cell visibility was a necessity for this study (for CFU counting), antibiotics 
were not used in other studies.   
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CFU Quantification 
Typical results for the cell-dilution CFU quantification method are shown in a M. 
JLS example in Figure 4.6.  The CFU concentration in this figure would be 1.1 x 108 
CFU/ml according to the most dilute spot and would be 6.1 x 107 CFU/ml according to 
the next most dilute spot, yielding an average of 8.55 x 107 CFU/ml and a standard 
deviation of 3 x 107.  Spectrophotometric CFU quantification was attempted in 
preliminary studies.  However, mycobacterial clumping decreased accuracy, and the 
results of such attempts are not shown here.  While the cell dilution CFU quantification 
method was more laborious, it proved to be more precise.       
 
EtOH/MeOH Toxicity Testing 
 
The cell growth/death results for M. KMS in MeOH and EtOH over a six-day 
period are shown in Figures 4.7 and 4.8, respectively.  Of both solvents, only the 4% 
EtOH concentration caused a decrease in M. KMS CFU population (10-fold decrease in 
the first four days), which rebounded somewhat in the following two days.  There were 
no significant differences seen between any of the other solvent concentrations and their 
no-solvent controls.  It was necessary to evaluate the toxicity of EtOH and MeOH to 
ensure any inhibitory/bactericidal effect was not due to the solvents.  MeOH and EtOH 
were the solvents chosen for this study since they were the most commonly used SJW 
solvents in literature.  The lower toxicity of MeOH reinforced the decision to use it as the 
SJW solvent for the duration of these studies.  In the MBC studies, the 2% (v/v) 
concentration was found to be the minimum organic solvent concentration that would still 
allow a high enough SJW crude extract concentration to consistently inhibit all 
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mycobacteria at more than one assayed concentration.  Hence, SJW extracts of various 
concentrations were most commonly added to cultures at 2% (v/v) concentration for the 
inhibitory/bactericidal studies. 
 
Crude Extract MIC Studies 
 
 Agar plates from the inhibitory studies are shown in Figure 4.9.  A trend of no 
growth at the higher SJW concentrations and growth at the lower SJW concentrations 
was seen, but a distinct threshold was not seen.  No growth was seen from the 8% - 1% 
plates (except one of the 1% plates), small growth was seen on the 0.5% - 0.25% plates 
and growth was seen on all other plates (except one of the 0.03% plates).  Therefore, a 
tentative MIC value from these plates would be between the 0.5% and 1% concentrations 
(of 1X stock solution).  However, with the understanding of the inhibitory effects of 
EtOH, which was shown to adversely affect cell growth at a 4% concentration in the 
solvent toxicity studies, inhibitory effect cannot be exclusively credited to the SJW 
extract.  Since any EtOH inhibition was uniform throughout all the plates (all plates had 
the same volume added, regardless of SJW concentration of the additive) and would only 
serve to reduce CFU population, the 0.5% - 1.0% 1X MIC value should be fairly 
accurate. 
 
Crude Extract MBC Studies 
 
 A typical set of CFU dilution growth plates for each strain, along with zoomed-in 
views of colonies from these strains, are shown in Figure 4.10.  All plates shown are from 
the 48-hr time point except B. subtilis, which is from the 24-hr time point (shown for 
clarity).  The absence of growth of cells that had been exposed to higher SJW 
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concentrations can be seen.  The MeOH control and no-MeOH/SJW control can be seen 
at the bottom two sections of the bottom plate in each image.  
 Typical growth/death results are shown in Figures 4.11 through 4.17.   MBC 
values are shown in Table 4.3.  Since the definition of MBC is the minimum 
concentration that kills ≥ 99.9% (three orders of magnitude) of the culture over a given 
period of time (which is considered 72 hr for this study), the 0.67 mg extract/ml culture 
would be considered a bactericidal concentration for M. MCS and M. phlei.  From most 
sensitive to least sensitive, the results show concentration sensitivity to the SJW MeOH 
extract in the following order: M. JLS and M. KMS, M. phlei, M. MCS, B. subtilis, M. 
smegmatis, and E. coli, which showed no sensitivity.  It should be noted that earlier 
studies showed that even though these differences exist in sensitivity over time, it was 
found that B. subtilis reacted the most quickly.  This conclusion was derived from earlier 
MBC studies, which considered the “time 0” time point to be immediately after adding 
the SJW extract.  Within the 0.5-hr to 1-hr timeframe it took to perform the first CFU 
quantification after SJW extract addition, the B. subtilis cultures had already been killed 
at the higher concentrations.  This effect is seen in Figure 4.18.  The 2.66 mg extract/ml 
concentration killed the cells within this timeframe, and the 0.67 and 1.33 mg extract/ml 
concentrations saw a rebound in cell growth over two days.  The rebound effect may be 
attributable to the fact that this cell dilution method does not detect CFU concentrations 
under 100 cells/ml and to the relatively fast doubling time of 30-45 min (depending on 
medium) for B. subtilis (Leitch and Collier, 1996).  This growth may also be attributable 
to resistant mutants and merits further study.  This immediate effect was not seen in any 
other strain assayed. 
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 It should be noted that Tween 80 (0.05% final concentration) was used in these 
crude extract MBC studies.  In the light of the purified compound MBC results shown 
below, the MBC values would likely be lower in the absence of Tween 80.                
 
Purified Compound MBC Studies 
 
 Hfn Inhibition and the Effect of Tween 80.  In the absence of Tween 80, Hfn 
caused bactericidal effects at the 26 µg/ml and 52 µg/ml concentrations (within 48 hr) 
and had inhibitory effects at the 6 µg/ml and 13 µg/ml concentrations (Figure 4.19).  In 
the presence of Tween 80 at 0.05% v/v concentration, no effect from Hfn, bactericidal or 
inhibitory, was seen (Figure 4.20).    
 The MBC values shown here are at least 65 times higher than the Hfn 
concentrations (approximately 0.4 µg/ml) found in rat and human blood after a high dose 
(1200 mg) of SJW extract taken orally (Biber et al., 1998).  Therefore, oral 
administration of the SJW herb does not reach adequate Hfn concentrations for 
mycobacterial death.  Studies involving Hfn administration techniques that bypass the 
digestive system for direct treatment, such as the use of inhalants (Gelperina et al., 2005; 
Shoyele and Cawthorne, 2006; Chow et al., 2007; Sung et al., 2007; Jaafar-Maalej et al., 
2009; Salama et al., 2009), merit investigation.   
 When keeping the Hfn concentration constant at 46 µg/ml (concentration in 1:50 
dilution (2% v/v) of 1X crude extract) and varying the Tween 80 concentration from 
0.003-0.1%, a decreasing ability of Hfn to inhibit mycobacterial growth was seen with 
increasing Tween 80 concentration (Figure 4.21).  The 0.1% Tween 80 concentration had 
the same approximate CFU count as the no-Tween80/Hfn control.  A Tween 80 dose-
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dependent CFU count reduction was observed with the 0.025% and 0.05% 
concentrations, and the more dilute Tween 80 concentrations reached CFU counts of 100 
CFU/ml or less over the 72-hr study.               
Effect of Tween 80 on MeOH Crude Extract.  The crude extract controls showed a 
similar pattern as Hfn.  In the absence of Tween 80, cell death was seen in all 
concentrations assayed: 0.33 (1/8X), 0.67 (1/4X), 1.33 (1/2X), and 2.66 (1X), mg 
extract/ml, which contained 6, 11, 23, and 46 µg/ml Hfn, respectively (Figure 4.22).  In 
the presence of Tween 80 (0.05%), the crude extract caused bactericidal effects in the 
1.33 mg extract/ml (23 µg/ml Hfn) only (2.7 mg extract/ml not tested) (Figure 4.23).  
Slight inhibitory effects (10-fold less) were seen in the 0.67 mg extract/ml (11 µg/ml 
Hfn).   
The difference in inhibitory effect seen in the absence and presence of Tween 80 
is significant.  This finding is important for any antimicrobial study for mycobacteria 
involving Tween 80; it may invite a reinvestigation of reported MIC/MBC values of 
other antimycobacterial agents if Tween 80 was used in the studies.  Whether the cause of 
this effect is an interaction between Tween 80 and Hfn or between Tween 80 and the 
bacterial cell wall remains to be studied.  It is known that Tween 80 affects the outermost 
layer of the cell wall (Parish and Stoker, 1998), which understanding could help in 
determining the mechanism of action for Hfn.  Another possible explanation for this 
effect is the formation of Tween 80 micelles around Hfn molecules, preventing the 
otherwise inhibitory Hfn from working.  Also, the fact that inhibition was seen in the 
crude extract samples containing 23 µg Hfn/ml, but not in the pure Hfn (23 µg/ml) 
samples when in the presence of Tween 80, suggests that the crude extract contains 
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compounds which either stabilize Hfn, interact with Tween 80, or interact with the 
bacterial cell wall to allow inhibition to occur at a higher degree than pure Hfn.   
  Effect of Hypericin and Pseudohypericin.  No bactericidal or inhibitory effects 
were seen in the Hpn or Phn samples at any assayed concentrations (Figures 4.24 and 
4.25).  However, a synergistic effect of these compounds with each other or with Hfn was 
not studied and merits investigation.   
  Effect of Light on Inhibition.  No significant effect of light on Hfn inhibition of 
M. KMS was seen.  Though the Hfn concentrations were not high enough to achieve 
MBC values, dose responses were seen in both the light-exposed tubes (Figure 4.26) and 
the tubes kept in the dark (Figure 4.27); these responses were remarkably similar. Due to 
an experimental error in the 24-hr CFU count for the control of the light samples, the 
value for the control from the dark samples was used for this particular time point.  From 
the results of these studies, it was decided to not investigate the effects of light any 
further.   
 
SEM Imaging 
 
 The results from SEM imaging are shown in Figures 4.28 – 4.32.  Figure 4.28 
shows untreated images of all the bacteria used in the MBC experiments.  Figure 4.29 
shows the untreated image of M. KMS again along with its response to the 1.33 mg 
extract/ml crude extract treatment at times 4, 8, and 24 hr.  Figure 4.30 shows the 
progressive response of M. smegmatis to 2.66 mg extract/ml crude extract treatment at 
times 12, 24, and 48 hr in addition to its control.  Figure 4.31 shows the B. subtilis 
response to 1.33 mg extract/ml treatment at times 30 min, 1 hr, and 2 hr in addition to its 
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control.  Figure 4.32 shows the response of E. coli to 2.66 mg extract/ml treatment after 
72 hr in addition to its control.   
 While no visible or experimental effect can be seen in the response of E. coli to 
SJW (other than a darkening of the media beyond the darkness of the extract addition, 
which effect was not studied), there appears to be a trend in the response of the SJW-
susceptible organisms to the crude extract: (1) an increase in field debris - whether or not 
this is cell debris or extract debris (<0.2 µm because of filtered extract) is uncertain, but it 
is suspected to be cell debris, as it is not seen in the treated E. coli images; (2)  a 
“beading,” or blistering effect in the cell wall; and (3) cell wall splitting, cracking, or 
rupturing, which leads to spilling of the cell contents.  Cell death is known to occur 
before the third part of the cell degradation trend, based on times from the MBC results.  
It is suspected that cell death occurs closer to the second phase.  These results support the 
MBC results, which show B. subtilis as having the most rapid SJW response.  These 
results also suggest that there is either a direct chemical interaction with the cell wall or 
an interference with genetic cell wall maintenance.  
 
Conclusions 
 The results from this chapter show a M. tuberculosis homology comparison to all 
nonpathogenic, genetically sequenced mycobacteria for M. MCS (72%), M. smegmatis 
(69%), M. KMS (69%), M. vanbaalenii (67%), M. JLS (66%), and M. gilvum (65%).  
SJW compounds are effective at inhibiting every currently sequenced, nonpathogenic 
Mycobacterium isolate, as well as M. phlei, which has not yet been sequenced.  There is 
no visible difference in the level of growth of mycobacteria between LB media and MB 
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media, but LB media produces more vibrant mycobacterial pigmentation, which makes 
colonies easier to see and quantify.  The five Mycobacterium isolates assayed in the MBC 
studies are resistant to ampicillin, but cell pigmentation is reduced when grown on Amp 
agar media.  EtOH has a higher toxicity to M. KMS than MeOH, though only in reducing 
CFU population 10-fold at the highest concentration tested (4% v/v).  MeOH has no 
toxicity to any of the assayed strains at the concentrations most often used in this study 
(2-4% v/v).  No inhibition difference has been seen between SJW extracts of different 
solvents, though this has only been assayed at a 4% (v/v) concentration of an extract from 
a 0.36 mg herb/ml solvent solution.  Depending on concentration, the MeOH SJW extract 
is inhibitory and bactericidal to (mg extract/ml culture) M. JLS (0.33-0.67), M. KMS 
(0.33-0.67), M. MCS (0.33-0.67), M. smegmatis (1.33-2.66), M. phlei (0.33-0.67), and the 
Gram-positive control B. subtilis (0.67-1.33); it has no effect on the viability of E. coli at 
the concentrations assayed.   
An MIC value for the SJW EtOH extract has been determined for M. KMS (0.5-
1% v/v of an extract from a 0.36 mg herb/ml solvent solution) using the dilution-in-agar 
method.  In the absence of Tween 80, Hfn has a MBC of 6-13 µg/ml for M. JLS.  Tween 
80 represses Hfn inhibition of M. JLS at Tween 80 concentrations of ≥ 0.025% (v/v) at 46 
µg/ml Hfn (Hfn concentration in 2.66 mg extract/ml); this may be due to micelle 
formation around Hfn molecules or an interaction of Tween 80 with the cell wall.  Tween 
80 also raises the MBC of M. JLS when used with the crude extract, but not to the degree 
seen with pure Hfn, even if both solutions have the same Hfn concentration; this may be 
due to a synergistic inhibitory effect of another SJW compound with Hfn, protection of 
Hfn from the effects of Tween 80, or a direct interaction of crude extract compounds with 
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the cell wall.  Tween 80, however, helps to reduce clumping and solubilize the SJW 
extract in culture and makes the cell dilution CFU quantification method more accurate.  
Hpn and Phn do not have an inhibitory effect on M. JLS at the concentrations assayed.  
Light does not appear to affect the inhibitory effect of Hfn.  SEM imaging suggests that 
SJW has an effect on the cell wall integrity/maintenance of the susceptible organisms, 
which knowledge should help in future studies of determining the mechanism of action.  
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Table 4.1  Inhibition demonstration of SJW extracts of various solvents and various 
SJW brands after one week of growth on crude-extract-containing plates (4% extract, 
v/v).  Degree of growth is indicated by number of plus signs, and no growth is indicated 
by a minus sign.  Some responses were not determined (ND) due to fungal 
contamination.  Controls (shown at bottom) contained solvent only.   
 
Nature’s	  Way	   Acetone	   Ethanol	   Ethyl	  Acetate	   Methanol	   Chloroform	   Water	  
M.	  JLS	   -­‐	   -­‐	   -­‐	   -­‐	   +++	   +++	  
M.	  KMS	   ND	   ND	   ND	   -­‐	   ND	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   ++	   +++	  
M.	  van.	  PYR-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
M.	  gilvum	  PYR-­‐GCK	   -­‐	   -­‐	   +++	   -­‐	   +++	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
NOW	   	   	   	   	   	   	  
M.	  JLS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  KMS	   ND	   -­‐	   -­‐	   -­‐	   -­‐	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  van.	  PYR-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  gilvum	  PYR-­‐GCK	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
GNC	   	   	   	   	   	   	  
M.	  JLS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  KMS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
M.	  van.	  PYR-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
M.	  gilvum	  PYR-­‐GCK	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
Controls	  (solvent	  only)	   	   	   	   	   	   	  
M.	  JLS	   +++	   +++	   +++	   +++	   +++	   +++	  
M.	  KMS	   ND	   ND	   ND	   ND	   ND	   +++	  
M.	  MCS	   +++	   +++	   +++	   +++	   +++	   +++	  
M.	  van.	  PYR-­‐1	   +++	   +++	   +++	   +++	   +++	   +++	  
M.	  gilvum	  PYR-­‐GCK	   +++	   +++	   +++	   +++	   +++	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	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Table 4.2  Inhibition demonstration of SJW extracts of various solvents and various 
SJW brands after two weeks of growth on crude-extract-containing plates (4% extract, 
v/v).  Degree of growth is indicated by number of plus signs, and no growth is indicated 
by a minus sign.  Some responses were not determined (ND) due to fungal 
contamination.  Controls (shown at bottom) contained solvent only. 
 
Nature’s	  Way	   Acetone	   Ethanol	   Ethyl	  Acetate	   Methanol	   Chloroform	   Water	  
M.	  JLS	   -­‐	   -­‐	   -­‐	   -­‐	   +++	   ++	  
M.	  KMS	   ND	   -­‐	   ND	   ND	   ND	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   ++	   ++	  
M.	  van.	  PYR-­‐1	   -­‐	   ND	   -­‐	   -­‐	   -­‐	   -­‐	  
M.	  gilvum	  PYR-­‐GCK	   +	   ND	   ++	   ND	   +++	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
NOW	   	   	   	   	   	   	  
M.	  JLS	   ND	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  KMS	   ND	   -­‐	   -­‐	   -­‐	   -­‐	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  van.	  PYR-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
M.	  gilvum	  PYR-­‐GCK	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
GNC	   	   	   	   	   	   	  
M.	  JLS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +++	  
M.	  KMS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ND	  
M.	  MCS	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   ++	  
M.	  van.	  PYR-­‐1	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
M.	  gilvum	  PYR-­‐GCK	   -­‐	   -­‐	   -­‐	   -­‐	   +	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	  
	   	   	   	   	   	   	  
Controls	  (solvent	  only)	   	   	   	   	   	   	  
M.	  JLS	   +++	   +++	   ++	   ++	   ++	   +++	  
M.	  KMS	   ND	   ND	   ND	   ND	   ND	   +++	  
M.	  MCS	   ++	   +++	   ++	   ++	   ++	   +++	  
M.	  van.	  PYR-­‐1	   ++	   ++	   ++	   +	   ++	   +++	  
M.	  gilvum	  PYR-­‐GCK	   +++	   +++	   +++	   ++	   +++	   +++	  
P.	  putida	   +++	   +++	   +++	   +++	   +++	   +++	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Table 4.3  Minimum bactericidal concentrations for the 
seven MBC-assayed strains. 
 
Strain	   SJW	  MBC	  (mg	  extract/ml	  culture)	  
M.	  JLS	   0.33-­‐0.67	  
M.	  KMS	   0.33-­‐0.67	  
M.	  MCS	   0.33-­‐0.67	  
M.	  smegmatis	   1.33-­‐2.66	  
M.	  phlei	   0.33-­‐0.67	  
E.	  coli	   N/A	  
B.	  subtilis	   0.67-­‐1.33	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Figure 4.1  Venn diagram for genetic similarity of all currently sequenced, 
nonpathogenic mycobacteria to M. tuberculosis.  Comparisons are made using amino 
acid sequences.  Non-percentage numbers indicate number of genes.  Outer percentages 
indicate genome unique to each Mycobacterium isolate.  Middle percentages indicate 
percentage of each isolate genome similar to M. tuberculosis.  Inner percentages indicate 
percentage of M. tuberculosis genome incorporated in each isolate (of greatest interest for 
this study).    
 
 
 
 
Figure 4.2  The five Mycobacterium strains used in the MBC studies: (starting in top 
right, going counterclockwise) M. JLS, M. KMS, M. MCS, M. smegmatis, and M. phlei.   
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Figure 4.3  Growth plates for demonstration of inhibitory effect and comparison of 
extracts of different solvents and different SJW brands.  Only the plates for the GNC 
brand are shown here.  Organisms on plate are as follows (starting at top, going 
counterclockwise): P. putida (G- control), M. vanbaalenii, M. gilvum, M.  MCS, M. JLS, 
M. KMS.  Because this particular extract used was not filtered, fungal growth occurred in 
several of the M. KMS sections; these were classified as “not determined.”   
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Figure 4.4  Comparison of mycobacterial growth on LB 
and MB media.  Dark background behind plates is to 
show contrast.  For the USU isolates (top three), growth 
on LB media provided higher bacterial visibility.   
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Figure 4.5  Growth comparison of five Mycobacterium isolates on 
antibiotic-free LB (left) plates and ampicillin-containing LB (50 µg/ml, 
right) plates.  Organisms assayed were (starting at top and going 
clockwise) M. JLS, M. KMS, M. MCS, M. smegmatis, and M. phlei.  A 
higher degree of cell pigmentation was seen on the antibiotic-free plates, 
so antibiotic-free media was used in all studies for consistency and to 
enable the easier use of the cell dilution method for CFU quantification.    
 
 
 
 
Figure 4.6.  Typical example of CFU 
quantification results using the cell dilution 
method (M. JLS).  The CFU count for this 
sample would be 1.1 x 108 CFU/ml according 
to the most dilute spot and would be 6.1 x 107 
CFU/ml according to the next lest dilute spot, 
yielding an average of 8.55 x 107 CFU/ml 
with a standard deviation of 3 x 107. 
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Figure 4.7  Effect of MeOH on M. KMS viability.  Concentrations assayed (v/v) were at 
final working volumes of 0.5%, 1.0%, 2.0%, and 4.0%, with a no-MeOH control 
included.  Error bars are standard deviation (SD). 
 
Figure 4.8  Effect of EtOH on M. KMS viability.  Concentrations assayed (v/v) were at 
final working volumes of 0.5%, 1.0%, 2.0%, and 4.0%, with a no-EtOH control included.  
Error bars are SD. 
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Figure 4.9  Growth plates from dilution-in-agar MIC study of SJW EtOH extract.  
Starting from upper left two plates and reading in columns, concentrations (% of 1X 
stock solution) were 8%, 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.13%, 0.07%, 0.03%, and 0%, 
performed in duplicate plates.  Organism key is on bottom right.   
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Figure 4.10  Typical cell dilution plates used for CFU quantification in 
MBC studies.  Concentrations assayed were 2X, 1X, 1/2X, 1/4X, 1/8X, 
and 1/16X, representing 4.5, 2.7, 1.3, 0.7, and 0.3 mg extract/ml, 
respectively.  The bottom right figures show zoomed in views of 
colonies from the dilutions to show cell morphology.  MeOH-only 
controls (denoted “MeOH”) and no-MeOH/SJW (denoted “None”) are 
the bottom two sections of the bottom plate of each isolate image.   
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Figure 4.11  Typical growth/death results of M. JLS from the crude extract MBC studies.  
SJW MeOH extracts of various concentrations were used at 2% (v/v) the total volume: 
0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  The MBC was between 0.33-0.67 
mg extract/ml.  Error bars are SD. 
 
 
 
Figure 4.12  Typical growth/death results of M. KMS from the crude extract MBC 
studies.  SJW MeOH extracts of various concentrations were used at 2% (v/v) the total 
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  The MBC was between 
0.33-0.67 mg extract/ml.  Error bars are SD. 
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Figure 4.13  Typical growth/death results of M. MCS from the crude extract MBC 
studies.  SJW MeOH extracts of various concentrations were used at 2% (v/v) the total 
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  The MBC was between 
0.33-0.67 mg extract/ml.  Error bars are SD. 
 
Figure 4.14  Typical growth/death results of M. smegmatis from the crude extract MBC 
studies.  SJW MeOH extracts of various concentrations were used at 2% (v/v) the total 
volume: 0.33, 0.67, 1.33, 2.66, and 4.46 mg extract/ml culture.  The MBC was between 
1.33-2.66 mg extract/ml.  Error bars are SD. 
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Figure 4.15  Typical growth/death results of M. phlei from the crude extract MBC 
studies.  SJW MeOH extracts of various concentrations were used at 2% (v/v) the total 
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  The MBC was between 
0.33-0.67 mg extract/ml.  Error bars are SD. 
 
Figure 4.16  Typical growth/death results of E. coli from the crude extract MBC studies.  
SJW MeOH extracts of various concentrations were used at 2% (v/v) the total volume: 
0.33, 0.67, 1.33, 2.66, and 4.46 mg extract/ml culture.  There was no SJW MBC for this 
strain.  Error bars are SD. 
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Figure 4.17  Typical growth/death results of B. subtilis from the crude extract MBC 
studies.  SJW MeOH extracts of various concentrations were used at 2% (v/v) the total 
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  The MBC was between 
0.67-1.33 mg extract/ml.  Error bars are SD. 
 
Figure 4.18  The time course of SJW effect on B. subtilis.  In early MBC studies, the 
“time 0” CFU count was taken immediately after adding the SJW extract, which would 
have been within about 1 hr. Cell growth rebound was seen in the 0.67 mg/ml and 1.33 
mg/ml concentrations.  The Mycobacterium isolates did not see such a rapid inhibition 
response.  Error bars are SD. 
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Figure 4.19  Growth/inhibition results for M. JLS treated with Hfn in the absence of 
Tween 80.  Concentrations assayed were 6, 13, 26, and 52 µg/ml culture.  The MBC was 
6-13 µg/ml.  Error bars are SD. 
 
Figure 4.20  Growth/inhibition results for M. JLS treated with Hfn in the presence of 
Tween 80 (0.05% v/v).  Concentrations assayed were 3, 6, 11, and 23 µg/ml culture.  
There was no MBC for these samples.  Error bars are SD. 
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Figure 4.21  Tween 80 repression of Hfn inhibition of M. JLS with all samples except the 
control containing 46 µg/ml Hfn.  Decreasing inhibition occurred with increasing Tween 
80 concentration.  The 0.1% concentration had similar CFU counts as the No-Tween 
80/Hfn control.  Decreasing CFU counts were seen in the 0.05% and 0.025% 
concentrations, and all lower Tween 80 concentrations reached CFU counts of 100 
CFU/ml or less over the 72-hr study.  Error bars are SD.   
 
Figure 4.22  Growth/inhibition results for M. JLS treated with crude extract (for 
comparison in the pure compounds MBC studies) in the absence of Tween 80.  
Concentrations assayed were 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture.  Inhibition 
was seen in all crude extract concentrations in this study.  Error bars are SD. 
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Figure 4.23  Growth/inhibition results for M. JLS treated with crude extract (for 
comparison in the pure compounds MBC studies) in the presence of Tween 80 (0.05% 
v/v).  Concentrations assayed were 0.17, 0.33, 0.67, and 1.33 mg extract/ml culture.  The 
MBC was between 0.67-1.33 mg extract/ml.  Error bars are SD. 
 
Figure 4.24  Growth/inhibition results for M. JLS at various concentrations of Hpn 
without Tween 80 added to the culture.  Concentrations assayed were 3, 7, 13, and 27 µg 
Hpn/ml culture.  No concentrations reached MBC levels.  Error bars are SD.     
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Figure 4.25  Growth/inhibition results for M. JLS at various concentrations of Phn 
without Tween 80 added to the culture.  Concentrations assayed were 3, 6, 13, and 25 µg 
Phn/ml culture.  No concentrations reached MBC levels.  Error bars are SD. 
 
Figure 4.26  Growth/inhibition results for the light-exposed samples (M. KMS) of the 
light/dark Hfn study.  Concentrations assayed were 0.1, 1, and 5 µg Hfn/ml culture.  The 
samples in light and dark had nearly identical results.  Error bars are SD. 
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Figure 4.27  Growth/inhibition curves for the foil-wrapped samples (M. KMS) of the 
light/dark Hfn study.  Concentrations assayed were 0.1, 1, and 5 µg Hfn/ml culture.  The 
samples in light and dark had nearly identical results.  Error bars are SD.   
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Figure 4.28  SEM images of untreated strains used in the SJW inhibitory/bactericidal 
assays.  (a) M. JLS, (b) M. KMS, (c) M. MCS, (d) M. smegmatis, (e) M. phlei, (f) E. 
coli, (g) B. subtilis       
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Figure 4.29  SEM images of the progression of M. KMS response to 
SJW MeOH crude extract (1.33 mg extract/ml).  Exposure at times (a) 0, 
(b) 4 hr, (c) 8 hr, and (d) 24 hr. 
81
 
Figure 4.30  SEM images of the progression of M. smegmatis response 
to SJW MeOH crude extract (2.66 mg extract/ml).  Exposure at times (a) 
0, (b) 12 hr, (c) 24 hr, and (d) 48 hr. 
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Figure 4.31 SEM images of the progression of B. subtilis response to 
SJW MeOH crude extract (1.33 mg extract/ml).  Exposure at times (a) 0, 
(b) 4 hr, (c) 8 hr, and (d) 24 hr. 
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Figure 4.32  SEM images of the response of E. coli to SJW MeOH 
crude extract (2.66 mg extract/ml).  Exposure at times (a) 0 and (b) 72 
hr. 
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CHAPTER 5 
 
EFFECT OF HYPERICUM PERFORATUM ON HUMAN  
 
ALVEOLAR EPITHELIAL CELLS 
 
 
Introduction 
 
  The aim of this study was to investigate the potential of using one or more of the 
SJW compounds as an inhalant for TB.  Therefore it was decided to investigate the effect 
of these compounds on the human carcinomic alveolar epithelial lung cell line A549.  
Studies were performed that investigated the effects of MeOH, SJW MeOH crude extract, 
Hpn, Phn, Hfn, and M. JLS cells on A549 cell viability.   
 
Materials and Methods 
 
 
A549 Media (Ham’s) Preparation 
 
 The protocol for A549 media (Ham’s) preparation is in the Appendix.   
 
 
A549 Cell Culturing  
 
A549 Culturing from Freezer Stock.  Freezer stocks of A549 (1-ml stocks), about 
16th subculture, were obtained from Dr. Soonjo Kwon from the USU Biological 
Engineering Tissue Engineering Laboratory.  Cell cultures were started from -80ºC 
freezer stocks by adding the cells to a tissue-culture-treated T25 (25 cm2) or T75 flask 
(75 cm2) (BD, Fisher Scientific, Pittsburgh, PA).  Warmed (37ºC) media was then added 
to the cells (5 ml for T25 or 12 ml for T75).  If the flask did not have a vent cap, the lid 
was left slightly open to allow gas exchange.  Cells were incubated in a CO2 incubator 
85	  
	  
(model 3531, Fisher Scientific, Pittsburgh, PA) at 37ºC and 5% CO2.  Media was 
changed every 2 or 3 days.   
Subculturing.  To subculture the cells, the old media was removed, and 0.05% 
trypsin EDTA (Invitrogen, Carlsbad, CA) was added in volumes of 50-250 µl/cm2.  The 
flasks were then incubated at 37ºC for 5-15 min until the cells had completely detached 
from the surface.  Visual confirmation of cell detachment was done using an inverted 
microscope.  About 5 ml media was added to inhibit the trypsin, and this cell solution 
was transferred to a 15-ml centrifuge tube.  Another 5-ml media was added to rinse any 
remaining cells from the flask and was also added to the centrifuge tube.  The tube was 
centrifuged for 10 min at 1000 RPM (834 RCF), and supernatant was discarded.  A 4-ml 
volume of warmed media was added, and the cells were gently resuspended.  A simple 
subculture consisted of splitting this volume evenly between two or more flasks and 
bringing the culture volume to the correct level with media.   
Cell Seeding at Specific Densities in Well Plates.  If a specific cell seeding density 
was desired, a Hausser Scientific Bright-Line hemacytometer (Fisher, Pittsburgh, PA) 
was used to determine cell concentration (Figure 5.1).  After cleaning the cell chamber 
surface and cover slide, the cover slide was placed firmly over the two chambers, and 10 
µl of resuspended cell solution was added to one of the chambers via an injection slot.  
Capillary action filled the chamber.  Using an inverted microscope, four cell counts were 
taken from four 1 mm2 x 0.1 mm deep squares (divided into 16 smaller squares for easier 
counting).  The counts were averaged and multiplied by 104 to obtain cells/ml.  Cell 
concentrations were adjusted by diluting with media and adding to a 6-well (9.6 
cm2/well) or 48-well (0.75 cm2/well) tissue culture plate (BD Falcon, Fisher, Pittsburgh, 
86	  
	  
PA).  Seeding densities ranged from 6.6x104 to 2.6x105 cells/cm2 in the A549 viability 
studies (approximately 1.3x104 cells/ml would reach confluency in 48 hr).   
Freezer Stock Preparation.  Freezer stocks of the A549 cells were made by 
preparing a 5% (v/v) dimethyl sulfoxide (DMSO) (Fisher Bioreagents, Pittsburgh, PA) 
cell solution after the centrifugation and resuspension steps of subculturing.  The solution 
was aliquoted into 1.5-ml Bio Plas microcentrifuge tubes (Fisher, Pittsburgh, PA) and 
stored at -70ºC.  Cells were stored in cryopreservation tubes in liquid nitrogen (-196ºC) 
for long-term storage.  
 
Treatments of A549 Cell Cultures 
 
 Various treatments were assayed for effect on A549 cell viability: MeOH, SJW 
MeOH crude extract, Hpn, Phn, Hfn, and M. JLS cells.  Treatments were always added to 
confluent cultures after the first (“time 0”) sample was taken.  The MeOH treatment was 
assayed in 6-well plates, and all other treatments were assayed in 48-well plates.  MeOH 
was added at four concentrations in triplicate two weeks after seeding (2.6x104 
cells/cm2).  SJW MeOH crude extract (in triplicate) and Hfn (in duplicate) were added at 
various concentrations (always ≤ 2% v/v) three days after seeding (2.6x105 cells/cm2) for 
one study and one week after seeding (6.6x104 cells/cm2) for another study using glass 
syringes (Hamilton, Reno, NV).  Hpn and Phn were added in triplicate at various 
concentrations three days after seeding (2.6x105 cells/cm2) using glass syringes.  M. JLS 
cells were added in duplicate at 5x106 cells/cm2 to A549 cultures one week after seeding 
(6.6x104 cells/cm2); cell concentration was determined using an average of four 0.04 mm2 
squares (Figure 5.1) of the hemacytometer. 
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A549 Viability Testing 
Pierce Bicinchoninic Acid (BCA) Total Protein Assay.  To harvest cell material 
for the Pierce BCA total protein assay, media was removed from the plate wells, and each 
well was rinsed with phosphate-buffered saline (PBS) (HyClone, Fisher, Pittsburgh, PA).  
A 1% (v/v)(aq) Triton X-100 (Fisher, Pittsburgh, PA) solution was added to the cells in 
consistent volumes, at least enough to cover the cells (650 µl/cm2 was typical), for cell 
lysis.  The cells were then incubated at 37ºC for 45 min, then thoroughly scraped off 
using a 1-ml pipette tip and resuspended in the Triton solution.  The cells were 
transferred to 1.5-ml microcentrifuge tubes and stored at -80ºC until a Pierce BCA total 
protein assay (Thermo Scientific, Rockford, IL) was performed.  The protocol used was 
supplied with the kit (Thermo, 2010).   
 Direct Cell Counting.  To harvest cells for direct cell counting, cells were rinsed 
with PBS, detached with 200 µl of 0.05% trypsin EDTA (in like manner as was done 
when subculturing), and added to 300 µl Ham’s media for trypsin inactivation.  Direct 
cell counts were then taken using the hemacytometer (Figure 5.1).  Brightfield images 
were taken for many of the samples before cell removal (in wells) and after cell counting 
(while on the hemacytometer) using a Nikon Fluorescence Microscope (Eclipse Ti-DH, 
Nikon, Melville, NY) with attached camera (Cool Snap HQ2, Photometrics, Tucson, AZ). 
Statistical Analysis.  The direct cell counting results of the various A549 
treatments were analyzed for statistically significant differences between each other using 
the General Linear Modeling (GLM) Procedure with SAS statistical analysis software.  
The results were analyzed as a 4x10x2 factorial design, with 4 levels of time, 10 levels of 
“additives” (including the controls), and 2 replicates (each replicate value was taken by 
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averaging the four hemacytometer counts of each cell sample).  Results were then 
grouped by statistically significant differences using the Ryan-Einot-Gabriel-Welsh q 
(REGWQ) test.   
 
Testing Mycobacterial Growth in Ham’s  
Media 
 
 The five Mycobacterium strains assayed in the MBC studies were tested for 
ability to grow in Ham’s media by preparing two sets of 12-ml culture tubes, each tube 
containing 5-ml Ham’s media.  One set contained no antibiotics, and the other set 
contained penicillin-streptomycin (100 U/ml and 100 µg/ml, respectively). Each tube was 
inoculated with 100 µl freezer stock of bacteria and incubated at the proper temperatures.  
Growth was observed after eight days.   
 
Results and Discussion 
 
 
Effects of Treatments on A549 Cell  
Viability  
Statistical Analysis.  The residuals vs. normal percentiles plot of the A549 cell 
counts from the direct cell counting study showed adequate homoscedasticity.  Partial R2 
values of the treatments (proportion contribution to the final outcome, which all add to 1), 
as well as their degrees of freedom (DF) (number of values that are free to vary in the 
final statistical calculation), F-values (used to calculate p-values) and p-values (used to 
show statistical significance if under 0.05), are shown in Table 5.1.  SJW additive had the 
greatest effect (partial R2 0.441), followed by the interaction between additive and time 
(partial R2 0.282), followed by time (partial R2 0.240).   REGWQ grouping for the 
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additives is shown in Table 5.2, with means of different letters being significantly 
different from each other.  The groupings are as follows:  (A) the MeOH control, no-
MeOH control, M. JLS, and Hfn 3 µg/ml samples; (B) the Hfn 6 µg/ml, Hfn 11 µg/ml, 
and Hfn 23 µg/ml samples; (C) the Hfn 11 µg/ml, Hfn 23 µg/ml, and Hfn 46 µg/ml 
samples; (D) the Hfn 46 µg/ml, crude 1.33 mg extract/ml, and crude 2.66 mg extract/ml 
samples.   
MeOH Treatment.  Results for the effect of MeOH on A549 viability are shown in 
Figure 5.2. The higher protein concentrations from these plates (due to suspending the 
cells in a smaller relative volume of Triton X-100 than the assays that used 48-well 
plates) were corrected by dividing by the fold-size difference in the 6-well and 48-well 
surface area (9.6/0.75 = 12.8).  The order of total protein concentration (high to low) was 
0%, 1%, 3%, and 2%, with a mean of 48.5 µg/ml +/- 2.2 (std. dev.).  There was no 
pattern seen in the treatment responses.  No statistically significant differences were seen 
between the concentrations using the GLM procedure in the SAS (3 DF, F-value: 4.00, p-
value: 0.0518) program.  Therefore, MeOH concentrations up through 3% did not have 
an effect on A549 viability. 
SJW MeOH Crude Extract Treatment.  The Pierce BCA protein assay was not 
effective at quantifying protein from the crude extract treatment due to the brown cell 
staining that the cells received from the crude extract.  This caused OD readings that were 
much higher than the controls (Figure 5.3).  Therefore, efforts to quantify A549 cells 
treated with crude extract with colorimetric assays were abandoned, and the direct cell 
counting method was used. 
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Results showing the use of the direct cell count method are shown in Figure 5.4.  
Cell death in both of the crude extract samples (1.33 and 2.66 mg extract/ml) was seen 
after one day.  Cell death was interpreted to be the absence of cells after PBS rinsing or a 
non-round, shredded, cell morphology (different from all other viable cells, which were 
round and intact).  Such morphology is seen in the crude-extract-exposed A549 cell 
images in Figures 5.5-5.7.  Viable cells (as seen in the controls) were flat, adhered to the 
plate, and tessellated; nonviable cells were round and detached (at least to some degree).  
It should be noted that the cells treated with crude extract did not detach from the well 
surface or disaggregate with trypsin treatment, even after rinsing off the media with PBS.  
Mild scraping was required to remove the cells from the wells.  This same effect was 
seen with the A549 samples in the protein assay after crude extract treatment; they also 
did not detach with PBS rinsing.  It is unknown why this occurred, but it is possible that 
the crude extract contains a trypsin inhibitor.  It is also possible that the crude extract 
contains one or more compounds that change the properties of the A549 cell membranes, 
causing them to adhere to the well surface and each other, even after cell death.     
Hyperforin Treatment.  The Hfn-treated cells were the only cells with a 
conclusive effect from the Pierce BCA protein assay (Figure 5.3).  After 2 days of 
exposure, rinsing with PBS completely removed the cells.  The direct cell count study 
revealed a dose-dependent response of the cells to Hfn, with the 11, 23, and 46 µg/ml 
concentrations causing complete cell death.  The half maximal lethal dose (LD50) 
(concentration that kills half the cell population) for the A549 cells in response to Hfn 
was 3-6 µg/ml (5.6-11.2 µmol/L).  There was usually no cell debris left behind after 
rinsing dead cells with PBS; however, cell debris was found in some Hfn samples and 
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were included in the images (see Figures 5.5-5.7).  Contrast between live and dead cells 
is easily apparent in the 3 and 6 µg Hfn/ml images in Figure 5.7.     
Thus far, no study has been found to investigate the effect of Hfn on the A549 cell 
line.  Though the results from this study do not show a lack of Hfn toxicity to primary 
human lung cells, the LD50 values found for Hfn in this study place the A549 cell line in 
line with a list of several other known human carcinomic (or immortal) cell lines to 
which Hfn is antiproliferative.  Thus, the A549 cell line may be added to this list and 
likely shares the same mechanism of action in Hfn-induced apoptosis (induction of 
mitochondrial-mediated pathway) (Schempp et al., 2002; Medina et al., 2006).  
Hypericin, Pseudohypericin, and M. JLS Treatments.  The Hpn and Phn 
treatments were only assayed with the Pierce BCA protein assay, which showed no 
significant viability effect at 28 µg/ml (Hpn) and 61 µg/ml (Phn).  The Hpn treatment did 
reach a LD50 value (based on the “time 0” value) at 72 hr, though this value had a 
relatively high standard deviation.  The Phn treatment reached a LD50 value at 48 hr, but 
cell numbers were above that value the following day.  However, the error in these ranges 
makes further testing of these compounds necessary, but merited, as hypericin is known 
to cause photosensitization and cell death in mammalian cells through high singlet 
oxygen yield (Agostinis et al., 2002).  Also, the effect of combinations of the hypericins 
(with each other and with Hfn) on A549 viability merits investigation.   
No statistically significantly different effect from the controls was seen in the 
A549 samples treated with M. JLS (at 5x106 bacteria/cm2).  The bacteria were added to 
media containing penicillin/streptomycin (10K U/ml and 10K µg/ml, respectively) and 
did not produce colonies after plating onto antibiotic-free LB agar plates.  The bacteria 
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were introduced in the same range as was used in similar studies (Lin et al., 1998).  As 
the M. JLS cells were nonviable, these results should be similar to the effect that would 
have been gained from adding mycobacterial cell components. 
 
Mycobacterial Growth in Ham’s Media 
The results of the growth test for all the bacterial strains from the MBC studies 
are shown in Table 5.3.  No strains grew in media containing Pen-Strep, and only M. JLS 
and E. coli grew in the antibiotic-free media.  These results may be of use for future 
studies on the effects of these strains on A549 cells when alive in culture, since the 
presence of dead M. JLS cells did not have a significant viability effect.   
 
Conclusions 
 
 The studies performed on the effect of SJW MeOH extract and compounds show 
that MeOH does not have a significant effect on A549 cell viability at or below 3% (v/v).  
Hpn and Phn concentrations of 28 µg/ml and 61 µg/ml, respectively, do not permanently 
or consistently lower the A549 cell count below LD50 values.  Hfn has a statistically 
significant effect on A549 cell viability at concentrations from 6 µg/ml to 46 µg/ml and 
does not at 3 µg/ml or lower.  Hfn also causes cell death at concentrations ≥11 µg/ml, 
with an LD50 of 3-6 µg/ml; this value is similar to a list of other carcinomic cell lines 
known to be sensitive to Hfn-induced apoptosis through a mitochondrial-mediated 
pathway, and these results justify the addition of the A549 cell line to that list.  The 
repeated failure of trypsin to detach/disaggregate crude extract-treated A549 cells from 
the plate surface and from each other suggests that either the crude extract contains a 
trypsin-inhibiting compound or that the extract somehow prevents cell detachment after 
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death.  The presence of nonviable M. JLS cells, at a concentration of 5 x 106 cells/cm2, 
does not show a statistically significant viability effect on A549 cells.  M.  JLS and E. 
coli grow in antibiotic-free Ham’s media.   
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Table 5.1  Statistical analysis parameters for the A549 samples from the 
direct cell count study.  Degrees of freedom show how many values are free 
to vary in the final statistical calculation.  Partial R2 values show what 
proportion a treatment or interaction has on the final outcome, and these 
values add to 1.  Additive (what was added to the A549 cells) had the 
greatest effect, followed by the interaction of additive and time, followed by 
time.  The F-value is used to determine the p-value, which if under 0.05, is 
considered statistically significant.       
 
	   Deg.	  Freedom	   Partial	  R2	   F-­‐value	   Pr>F	  (p-­‐value)	  
Time	   3	   0.24	   86.36	   <0.0001	  
Additive	   9	   0.441	   53.02	   <0.0001	  
Time*Additive	   27	   0.282	   11.31	   <0.0001	  
 
 
Table 5.2  Ryan-Einot-Gabriel-Welsh q (REGWQ) test for 
A549 cell treatments that received direct cell counting.  
Treatments are listed in descending order by mean.  Groups 
of each letter are statistically significantly different from 
other groups.   
 
Additive	   Mean	   N	   REGWQ	  Grouping	  
MeOH	  control	   45.9	   8	   A	   	  
No-­‐MeOH	  control	   45.2	   8	   A	   	  
M.	  JLS	   44.2	   8	   A	   	  
Hfn	  3	  µg/ml	   39.1	   8	   A	   	  
Hfn	  6	  µg/ml	   24.2	   8	   	   B	  
Hfn	  23	  µg/ml	   22.0	   8	   C	   B	  
Hfn	  11	  µg/ml	   21.0	   8	   C	   B	  
Hfn	  46	  µg/ml	   13.8	   8	   C	   D	  
Crude	  2.6	  mg	  extract/ml	   11.5	   8	   	   D	  
Crude	  1.3	  mg	  extract/ml	   9.9	   8	   	   D	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Table 5.3  Growth results in Ham’s media of all 
Mycobacterium isolates used in the MBC studies.  Growth 
is marked by a “Y” or “N” for yes or no. 
 
Strain	   No	  Antibiotic	  
Containing	  Pen-­‐Strep	  
(100	  U/ml,	  100	  µg/ml)	  
M.	  JLS	   Y	   N	  
M.	  KMS	   N	   N	  
M.	  MCS	   N	   N	  
M.	  smegmatis	   N	   N	  
M.	  phlei	   N	   N	  
E.	  coli	   Y	   N	  
B.	  subtilis	   N	   N	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Figure 5.1  The improved Neubauer Bright-Line Hemacytometer setup 
(www.hausserscientific.com). The surface is 100 µm deep.  The four 1-mm2 
sections (highlighted in red) were used to calculate A549 cell concentration, and 
each section gives cells/100 nl.  The four smaller, 0.04-mm2 sections 
(highlighted in blue) were used to calculate bacterial concentration, and each 
section gives cells/4 nl.   
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Figure 5.2  Pierce BCA total protein assay for the effect of MeOH on A549 viability.  
No statistically significant viability differences were seen.  Cells were assayed at 
concentrations from 0-3% and harvested at 72 hr exposure.  Error bars are SD. 

Figure 5.3 Pierce BCA total protein assay results for Hpn, Hfn, Phn, and SJW MeOH 
crude extract at concentrations found in the 4.46 mg extract/ml crude extract.  Due to cell 
staining by the crude extract, the protein assay gave OD readings that were much higher 
than the controls.  Imprecise results were seen with the other samples.  Cell death was 
seen, however, in the Hfn sample.  Error bars are SD. 
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Figure 5.4  Direct cell count results (2 replicates, 4 counts each) for effect of dead M. 
JLS cells, SJW MeOH crude extract, and Hfn on A549 cell viability.  Cell death occurred 
with the 1.33 and 2.66 mg extract/ml crude extract concentrations and in the 11, 23, and 
46 µg/ml Hfn concentrations.  Cell death did not occur in the no-MeOH/SJW control, 
MeOH control, or M. JLS samples.  The Hfn LD50 value was 3-6 µg/ml.  Error bars are 
SD.  Corresponding images are seen in Figures 5.5-5.7.  
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Figure 5.5  24-hr exposure of A549 cells to dead M. JLS 
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66 
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).  
Cell death occurred in the crude extract samples and in 
the three highest-concentrated Hfn samples, with a Hfn 
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L).  Cell morphology 
shown in bottom right of each image.   
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Figure 5.6  48-hr exposure of A549 cells to dead M. JLS 
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66 
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).  
Cell death occurred in the crude extract samples and in 
the three highest-concentrated Hfn samples, with a Hfn 
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L).  Cell morphology 
shown in bottom right of each image.   
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Figure 5.7  72-hr exposure of A549 cells to dead M. JLS 
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66 
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).  
Cell death occurred in the crude extract samples and in 
the three highest-concentrated Hfn samples, with a Hfn 
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L).  Cell morphology 
shown in bottom right of each image. 
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CHAPTER 6 
 
ENGINEERING APPLICATIONS AND FUTURE CONSIDERATIONS 
 
 
 Several potential engineering applications or considerations of this research, as 
well as possible future directions, are listed below: 
 
Engineering Applications and Considerations 
 
1. Investigating the optimal droplet size of Hfn aerosols for delivery to the lungs.   
2. Micro- or nano-encapsulating SJW compounds in a dissolving suspension, 
looking into the possibility of a time-released treatment.  
3. Looking into the design of encapsulation materials, taking into consideration 
lipophilicity, dissolving rate, and surface wetting (for cell adhesion) parameters. 
A polymeric material such as poly (lactide-co-glycolide) (PLGA) could be used.   
4. Undertaking a direct focal delivery study of SJW-compound-encapsulation 
particles, engineering the surface of the particles to preferentially adhere to the 
cell surfaces of TB granulomas.  This would enable the use of higher medication 
concentrations and minimize toxicity to healthy cells.   
5. Investigating mass transfer rates of SJW compounds in cell culture, developing 
mass transfer vs. penetration depth charts.   
6. Determining values for exposure time and frequency of treatment with SJW 
compounds to adequately repress or kill Mycobacterium strains in lung cell 
models.   
7. Investigating the surface-coating rates of nebulized liquid, microparticles, and 
nanoparticles containing SJW compounds.  This investigation could also look into 
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developing models which would predict necessary medication flow rates to coat 
only a given percentage of cell surface area at a time; the idea of this would be to 
allow oxygen transfer to the lung cells while still uniformly coating the cell 
surface over time.  
8. Employing the use of fluorescent particles (such as quantum dots that fluoresce in 
the tissue-transmission range) that are attached to mycobacterial-specific 
antibodies for locating mycobacterial infection sites in the lungs.  Successes in 
this area could reduce or eliminate the need for using X-rays in TB screening.    
9. Using mycobacterial-specific antibodies in materials used in targeted drug 
delivery (such as the above-mentioned nanoparticles) to mycobacteria in the 
lungs.  Lung-cell models treated with dead Mycobacterium cells (or live if using 
non-antibiotic-containing media), which have been shown to be a viable option as 
a result of this study, could make adequate models.   
10. Developing a cancer-screening method that detects Hfn metabolites.  It is known 
that Hfn affects carcinomic cells, and it may be possible that only these types of 
cells metabolize this compound.   
11. Investigating systemic Hfn treatment parameters in animals (after appropriate in 
vitro screening) to investigate Hfn effectiveness in metastatic prophylaxis.   
12. Looking into the viability (based on successes in the previously mentioned 
applications in this section) of a home-treatment option for TB patients.  
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Future Work Recommendations (In Order of Priority) 
 
1. Performing viability and inflammatory assays of pure Hfn against primary lung 
cells and other primary human cells to determine if the Hfn levels at which 
inflammation or cell death occurs is sufficiently above the Hfn levels known to 
cause apoptosis in carcinomic cell lines.  Such studies should also include other 
SJW compounds to investigate their effects.  Viability assays would likely include 
direct cell count and live-dead fluorescence assays.  Inflammatory assays would 
likely include cell membrane integrity, metabolic function, and interlueken-8 
assays.  Findings from such studies would be beneficial for both 
antimycobacterial and cancer research.   
2. Narrowing in on the mechanism of action for Tween 80 repression of Hfn 
inhibition of mycobacteria.  Such studies would include treating a non-
mycobacterial, Hfn-susceptible strain (such as B. subtilis) with the same Hfn 
concentration and variable Tween 80 concentrations (similar to the study shown 
in Figure 4.21).  A variation of this study that would use mycobacteria but other 
known mycobacterial antibiotics instead of Hfn should also be done to see if the 
Tween 80 effect is Hfn-specific.  Antibiotics chosen should include those that 
affect the cell wall more directly (INH, EMB) and those that affect the cell in 
other ways (RIF, SM).  Findings from this study may also contribute to 
discovering the Hfn mechanism of action if the Tween 80 Hfn repression is due 
only to modification of outermost layer of the cell wall.   
3. Investigating the surfactant that is known to be present in the lungs (Foster et al., 
1998) and assaying this surfactant (or surfactants other than Tween 80) in SJW 
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inhibitory assays against mycobacteria to see if the Tween 80 Hfn-repression 
effect seen with M. JLS is specific to Tween 80.  This would help determine if 
Hfn treatment of TB through inhalation is a viable option. 
4. Conducting further studies to investigate the mechanism of action for SJW crude 
extract and Hfn in both mycobacteria and A549 cell inhibition/toxicity.  Such 
studies would likely employ the use of microarray technology to understand 
genetic induction/repression with SJW exposure.  Studies that assay for free 
mycolic acids or several other specific cell wall components may also be 
employed; such techniques have been used in determining the mechanisms of 
action with other mycobacterial antibiotics (Dover et al., 2008).  Another method 
may be to compare SEM images of bacteria treated with other mycobacterial 
antibiotics to images of bacteria treated with SJW compounds.   
5. Including binary or tertiary combinations of SJW compounds in assays that 
investigate their synergistic effects on both bacteria and lung cells.  It is possible 
that a combination of compounds has a more potent inhibitory or bactericidal 
effect than Hfn alone.  The SJW inhibitory studies presented in Chapter 4 showed 
a more rapid inhibition response with the crude extract than with pure Hfn, even if 
both had the same Hfn concentration; combination studies would be a first step to 
discovering the reason for this.  No such study has been seen in literature.   
6. Investigating the stability of Hfn in blood.  Such understanding would be critical 
for correct dosage administration.  It would also be one of the first steps of 
investigation for the possibility of using Hfn for metastatic cancer treatment.          
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7. Comparing the effects of SJW extracts of different organic solvents in more detail 
than was done in this study.  One such solvent would be ethyl acetate, which was 
shown in this study to produce a lighter-colored extract and may make 
colorimetric assay a more feasibly option.  As colorimetric assays are often less 
laborious than direct CFU or cell counting methods, this may make many aspects 
of SJW research more efficient.   
8. Investigating the cause of trypsin-EDTA ineffectiveness in detaching A549 cells 
after treatment with the SJW crude extract.  It may be possible that the MeOH 
extract contains a trypsin inhibitor, which may be useful for other biotechnology 
applications.   
9. Developing an HPLC preparative method to obtain greater quantities of SJW 
active compounds.  This would make pure compound studies possible in greater 
volumes of media, making concentration and volume variability due to 
evaporation less of an issue.  It would also allow the assaying of higher 
concentrations of the pure compounds against bacteria and mammalian cells.   
10. Refining the photoconversion/photodegradation parameters for SJW crude 
extracts, narrowing in on the Hpn/Phn-converting and Hfn-degrading 
wavelengths.  As seen from the Hfn degradation study in Chapter 5, using specific 
light conditions are important to maintaining accurate concentrations.  Knowing 
specific wavelengths at which degradation is avoided may eliminate unnecessary, 
burdensome precaution (such as working in overly dark conditions). 
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Luria (LB) Broth and Agar 
 
 
LB Broth   
LB broth was prepared by dissolving 10 g Bacto Tryptone (BD, Fisher, 
Pittsburgh, PA), 5 g Bacto yeast extract (BD, Fisher, Pittsburgh, PA) and 10 g sodium 
chloride (NaCl) (Fisher, Pittsburgh, PA) in 1 L ddH2O.  This solution was covered in foil 
and autoclaved at 121°C for 30 min.  The broth was stored at room temperature 
 
LB Agar   
If preparing agar LB for plates, 15 g Difco agar (BD, Fisher, Pittsburgh, PA) was 
added to the mixture above before autoclaving at the same temperature and time.  For 
agar plates, the agar was gently swirled immediately after autoclaving and allowed to 
cool in a laminar flow hood to approximately 55°C.  The agar was then poured into 
100x15 mm Petri dishes (Fisherbrand, Fisher, Pittsburgh, PA) in aliquots of 
approximately 25 ml.  After cooling for about 30 min with the lid cracked open to allow 
the plates to dry, the plates were placed in a bag and kept at 4°C until use.   
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Middlebrook (MB) 7H9 Broth and 7H10 Agar 
 
 
MB Broth   
To make MB 7H9 broth, 4.7 g of Difco Middlebrook 7H9 powder (BD, Fisher, 
Pittsburgh, PA) was suspended in 900 ml ddH2O (containing 2 ml glycerol or 0.5 g 
Tween 80, if desired) and autoclaved at 121ºC for 10 min.  When media had cooled to 
45ºC, 100 ml Middlebrook ADC Enrichment (BD, Fisher, Pittsburgh, PA) was added 
aseptically. 
 
MB Agar   
To make MB 7H10 agar, 19 g of Difco Middlebrook 7H10 powder (BD, Fisher, 
Pittsburgh, PA) was suspended in 900 ml ddH2O containing 5 ml glycerol.  After mixing, 
this solution was heated until boiling and boiled for 1 min to dissolve the powder.  It was 
then autoclaved at 121ºC for 10 min.  The agar was gently swirled immediately after 
autoclaving to resuspend the agar.  After cooling to 50-55ºC, 100 ml Middlebrook OADC 
Enrichment (BD, Fisher, Pittsburgh, PA) was added aseptically.  Agar was then poured 
into plates in aliquots of approximately 25 ml.  After cooling for about 30 min with the 
lid cracked open to allow the plates to dry, the plates were placed in a bag and kept at 4°C 
until use. 
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A549 Media Preparation 
 
 Nutrient mixture F-12 Ham’s media in powder form was obtained from Sigma-
Aldrich (N3520) (St. Louis, MO).  Each bottle was formulated for 1 L media.  The 
powder from one of these bottles was added to 900 ml purified H2O, and the residual 
powder from the bottle was rinsed and added to the solution.  Sodium bicarbonate 
(NaHCO3), 2.5 g, was added, and the pH was lowered to between 7.1 and 7.2 using 1N 
hydrochloric acid (HCl).  Another 100 ml purified H2O was added.  This solution was 
then 0.2-µm filtered and stored at 4ºC if it was not going to be used within two months 
(could be stored up to six months).  If media was needed soon, fetal bovine serum (FBS) 
(Invitrogen) was added at 10% the final media volume along with 100X Penicillin-
Streptomycin solution (10K U/ml and 10K μg/ml, respectively, from Thermo Scientific – 
Fisher) at 1% the final volume prior to use.             
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SEM Fixation Protocol 
  
The cell fixation protocol used by Drs. TC and FenAnn Shen for the SEM images 
is as follows: 
 
Reagents: 
 
1.  2% buffered gluteraldehyde 
 
23.83 grams HEPES in 40 ml 50% glutaraldehyde. Bring to 1L with DI water. 
-OR- 
23.83 grams HEPES in 250 ml 8% glutaraldehyde. Bring to 1L with DI water. Bring 
pH to 7.0. 
 
Note: Can use 30.24 g PIPES or 21.402 g sodium cacodylate trihydrate (toxic, 
contains arsenic) in place of HEPES.  PBS can also be used but leaves salt crystals. 
 
2.  1-2% osmium Tetroxide 
 
4 ml 4% osmium tetroxide, 4 ml 0.4M HEPES (95.32 g in 1L DI water), and 8 ml DI 
water. pH to 7.0. 
 
Note: If PIPES is used in 2% buffered glutaraldehyde, then use 120.96 g PIPES in 1 L 
DI water. If cacodylate used, then use 85.608 g sodium cacodylate trihydrate in 1 L 
DI water. 
 
3.  0.1M HEPES Buffer 
 
23.83 grams HEPES in 1 L of DI water. pH to 7.0 
 
Note: If PIPES used in 2% buffered glutaraldehyde, then use 30.24 g PIPES in 1 L DI 
water. If sodium cacodylate trihydrate is used, then use 21.402 g sodium cacodylate 
trihydrate in 1 L DI water.   
 
4.  50%, 70%, 95%, and 100% EtOH 
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Protocol 
 
1. Fix sample with 2% buffered glutaraldehyde. Fixative should be 10 to 20 times the 
volume of the sample. Let sit for 2 hr minimum. 
 
2. Rinse with 0.1 M HEPES buffer 3 times for 5 min each with gentle agitation. 
 
3. Post fix in 1-2% osmium tetroxide for 1 hr. 
 
4. Rinse with 0.1 M buffer 3 times for 5 min each. 
 
5. Alcohol series dehydration: 
- 50 % EtOH, 2 times for 10 min each with agitation. 
- 70 % EtOH, 2 times for 10 min each with agitation. 
- 95 % EtOH, 2 times for 10 min each with agitation. 
- 100 % EtOH, 3 times for 15 min each with agitation. 
 
6. Keep in fridge until ready to dry and sputter coat. 
 
7. Dry. 
Option A: Use a critical point dryer. 
Option B: Chemical drying 
1. (2 parts 100% EtOH : 1 part HMDS) for 15 min. 
2. (1 part 100% EtOH : 1 part HMDS) for 15 min. 
3. (1 part 100% EtOH : 2 parts HMDS) for 15 min. 
4. HMDS alone for 15 min, 3 times. 
5. Let the last HMDS evaporate in a fume hood overnight. 
 
8. Mount samples on specimen stubs, sputter coat and view. 
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Notes 
 
1.  HMDS, glutaraldehyde, and osmium tetroxide are all toxic. They need to be put in 
separate bottles to be disposed. 
 
2.  The solid container that touches HMDS, glutaraldehyde, or osmium tetroxide needs to 
be put in a solid chemical waste box to be disposed. 
 
3.  HEPES is a buffer solution to wash off other chemicals without changing the pH 
values. 
 
4.  Glutaraldehyde is to stop biological process in an organism – chemical fixing. 
 
5.  Osmium tetroxide is to keep structure integrity when the organism is fixed. 
6.  HMDS is a chemical drying agent to remove water. Thus, the final step does not need 
water in the HMDS solution. 
 
 
 
 
